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ABSTRACT

MODULATION OF IMMUNITY VIA ANTIBODIES DISPLAYED ON IN SITU
FORMING PEPTIDE CO-ASSEMBLIES
By
Yi Wen
August 2014

Dissertation supervised by Wilson S. Meng, Ph.D.
Many diseases are associated with disruption of immune homeostasis. Monoclonal
antibodies (mAb) targeting soluble antigens or immune cell surface molecules have been
developed to modulate immunity. However, systemic administration can lead to severe
immune related side effects. This dissertation investigated a versatile platform to display
antibodies locally in diseased tissues to minimize unwanted systemic exposure.

This

system is a stimuli-responsive and injectable formulation utilizing in situ forming peptide
co-assemblies and two linker proteins. The self-assembling peptides EAK16-II and
EAKIIH6 co-assemble into fibrous structures with accessible His-tags when exposed to
salts. Anti-His-tag antibodies (αH6-IgG) bind to these His-tags and provide fragment
crystallizable region (Fc) for protein A/G (pAG).

A therapeutic antibody can be

displayed through non-covalent Fc-pAG interactions.

Proof-of-concept studies

demonstrate that antibodies were displayed via His-tags through the linker proteins,
iv

namely His-tag/αH6-IgG/pAG interactions. Displayed antibodies remained biologically
active and were able to bind to cognate antigens.

Upon administration to normal

subcutaneous space, tumors, or transplant sites, a fluorescent dye labeled IgG was
retained effectively at the site of injection. Antibodies targeting a cellular surface antigen
were loaded onto the peptide co-assembly. Displayed antibodies were able to interact
with cellular surface antigens and impede trafficking of target cells, resulting in potential
therapeutic response in a murine skin transplantation model. Characterization of the
peptide co-assembly indicates the His-tagged peptide (EAKIIH6) co-assembled with the
parent peptide (EAK16-II) in a concentration dependent manner. Comparing the coassembly efficiency of EAKIIH6 to other control peptides implies that EAKIIH6 might
adopt a β-strand conformation and align with existing EAK16-II β-sheets during coassembly. It was also found that the accessibility of His-tags could be tuned by changing
the ratio of peptides. To conclude, these results demonstrate the peptide co-assembly
based system could be used as a versatile antibody display system to modulate immunity.
It may have the potential to improve therapeutical outcomes of mAbs as a local antibody
delivery system, and it could also be utilized as a material strategy to immobilize target
cells.

v

DEDICATION

This dissertation is dedicated to my loving and supportive wife, Tiantian Gong, our
sweet little boy, Luke Boteng Wen, and to my loving and encouraging parents Jianqing
Wen and Huifang Li.

vi

ACKNOWLEDGEMENT

I would like to gratefully and sincerely thank my advisor, Dr. Wilson Meng, for his
guidance, understanding, and support through my PhD study. His mentorship and
friendship not only lead me to develop essential scientific and professional skills but also
to mature mentally as an individual. I would like to express my deepest gratitude to my
dissertation committee members, Dr. Ellen Gawalt, Dr. Ira S. Buckner, Dr. Jelena M.
Janjic, and Dr. Lauren A. O’Donnell for their valuable input and insightful comments as
well as access to instruments. I also want to extend my special thanks to Dr. Rita
Mihaelescu, Dr. Rehana K. Leak, and Mrs. Denise Butler-Buccilli for their help on
circular dichroism, ex vivo imaging, and animal studies. I would like to thank the
pharmaceutics faculty Dr. James K. Drennen III, Dr. Carl A. Anderson, Dr. Peter
Wildfong, and Dr. Laurence H. Block for the high quality training and education I
received at Duquesne.
I am grateful to our current and former group members for their help and friendship:
Ying Zheng, Wen Liu, Shana L. Roundebush, Jeffery R. Kovacs, Amanda George, and
Harrold R. Kolonich.

I also want to thank Kristen M. Kruszewski and Gavin A.

Buckholtz for their technique help on SEM and AFM. In addition, the friendship and
encouragement from all the graduate students has been a wonderful source of support.
Finally and most importantly, I would like to thank my wife, my son, and my parents,
for their endless love and support, without which, I cannot be where I am today.

vii

TABLE OF CONTENTS
ABSTRACT∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ iv
DEDICATION∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ vi
ACKNOWLEDGEMENT∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ vii
TABLE OF CONTENTS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ viii
LIST OF TABLES∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ xiii
LIST OF FIGURES∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ xiv
LIST OF ABBREVIATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙xvii
CHAPTER 1 Introduction ··········································································· 1
Statement of the problem ········································································· 1
Significance ························································································· 7
Antibody display system ········································································ 12
Project overview ················································································· 19
CHAPTER 2 Design, Mechanisms, and Applications of Ionic Complementary β-sheet
Self-Assembling Peptides ········································································· 22
Abstract ··························································································· 22
Introduction ······················································································· 22
Self-assembly of ionic complementary peptides ············································ 24
Rational design of self-assembling peptides ·············································· 24
viii

Effect of peptide composition on self-assembly ········································· 26
Effect of salts on self-assembly ····························································· 30
Effect of peptide concentration on self-assembly ········································ 31
Effect of pH on self-assembly ······························································ 31
Mechanism and hierarchy of self-assembly··············································· 32
Applications of ionic complementary self-assembling peptides ·························· 34
Tissue engineering and regeneration ······················································· 35
Drug delivery ·················································································· 39
Hemostasis ····················································································· 45
Pathogenesis of β-amyloids ································································· 45
Summary ·························································································· 46
CHAPTER 3 Retaining Antibodies in Tumors with a Self-assembling Injectable System
········································································································· 48
Abstract ··························································································· 48
Introduction ······················································································· 49
Materials and Methods ·········································································· 52
Materials ······················································································· 52
Sample preparations ·········································································· 53
Optical and scanning electronic microscopy·············································· 53
Sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE) ·············· 54
Antigen binding activity of immobilized antibodies····································· 54
Mice, tumor inoculation, and imaging ····················································· 55

ix

Tracking retention in vivo ··································································· 56
Statistical analysis ············································································ 57
Results ····························································································· 58
SDS-PAGE ···················································································· 60
Scanning electron microscopy ······························································ 63
Antigen binding activity of immobilized antibodies····································· 65
In vivo assembly and stability of EAK16-II/EAKIIH6 membrane co-assembly ···· 69
Stability of IgG displaying system in tumors ············································· 78
Discussion ························································································ 85
Conclusions ······················································································· 87
CHAPTER 4 Antibody Functionalized Peptidic Membranes Impede Trafficking of
Allogeneic Skin Antigen Presenting Cells ······················································ 89
Abstract ··························································································· 89
Introduction ······················································································· 89
Materials and Methods ·········································································· 96
Materials ······················································································· 96
Skin transplantation ·········································································· 96
In vivo stability of IgG membrane in subcutaneous space and under the skin graft 98
Detection of I-Ad+ dAPCs in draining lymph nodes ···································· 99
Allogeneic APC-T cells reaction ·························································· 100
Statistical analysis ··········································································· 100
Results ···························································································· 101
x

In vivo retention of IgG membranes in subcutaneous space ·························· 101
In vivo stability of IgG membranes under skin grafts ·································· 107
Evidence of impeded dAPCs trafficking to lymph nodes ······························ 110
Suppression of T cell responses in recipient mice ······································ 113
Discussion ······················································································· 117
Conclusions ······················································································ 120
CHAPTER 5 Co-assembly of Amphiphilic Peptide EAK16-II with Histidinylated
Analogues and Implications for Functionalization of β-sheet Fibrils in vivo ············· 122
Abstract ·························································································· 122
Introduction ······················································································ 123
Materials and Methods ········································································· 126
Peptides and reagents ······································································· 126
Gel electrophoresis ·········································································· 126
Fluorescent measurement and microscopy ··············································· 127
Spectroscopic analyses of peptide conformations ······································ 128
Mice and in vivo clearance ································································· 128
Statistical analysis ··········································································· 129
Results ···························································································· 130
Self-sorting of EAKIIH6 ··································································· 130
Conformations of EAKIIH6································································ 132
Dilution of EAKIIH6 in EAK16-II ······················································· 135
In vitro His-tag accessibility ······························································· 140
xi

In vivo His-tag accessibility ································································ 143
Discussion ······················································································· 150
Conclusions ······················································································ 155
CHAPTER 6 Summary and Future Directions ················································ 158
REFERENCES∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙161

xii

LIST OF TABLES
Table 1-1 Therapeutic mAb approved or in review. ........................................................... 3
Table 1-2 Stoichiometry of the antibody display system.................................................. 18
Table 2-1 Summary of self-assembling peptides studied. ................................................ 25
Table 2-2 Sequences of the amphiphilic peptides studied. ............................................... 27
Table 5-1 Peptide formulations used for determining His-tag retention (AUC) in vivo. 149

xiii

LIST OF FIGURES
Figure 1-1 Therapeutic mechanism of Ipilimumab, an anti-CTLA-4 antibody.................. 5
Figure 1-2 Proposed multivalent interactions between displayed antibodies and target cell.
........................................................................................................................................... 10
Figure 1-3 Schematic depiction of the self-assembling of EAK16-II. ............................. 13
Figure 1-4 Peptide sequence and chemical structures of EAK16-II and EAKIIH6. ........ 16
Figure 1-5 Schematic illustration of the peptide co-assembly and antibody display system.
........................................................................................................................................... 17
Figure 2-1 EAK16-II peptide in β-strand conformation. .................................................. 25
Figure 2-2 Schematic representation of cooperative hydrophobic interactions among
hydrophobic residues of different sizes. ........................................................................... 28
Figure 2-3 Molecular model of RADA16-I assembly. ..................................................... 33
Figure 2-4 Molecular models of functionalized peptides and peptide co-assembly. ........ 38
Figure 2-5 Graphic representation and release profiles of lysozyme, trypsin inhibitor,
BSA, and IgG in 1% (w/v) RADA16-I hydrogels. ........................................................... 41
Figure 2-6 Tethering of biotinylated IGF-1 to biotinylated self-assembling peptides via
biotin-streptavidin interactions. ........................................................................................ 43
Figure 3-1 Schematic depiction of the IgG displaying system. ........................................ 51
Figure 3-2 Optical micrographs of samples. ..................................................................... 59
Figure 3-3 Analysis of interactions in the membrane system using SDS-PAGE
electrophoresis. ................................................................................................................. 61
Figure 3-4 SEM images of samples. ................................................................................. 64
Figure 3-5 Antigen binding function of immobilized αTGF-β IgG.................................. 67
xiv

Figure 3-6 Stability of EAK16-II/EAKIIH6 (molar ratio 4:1) co-assembly in BALB/c
mouse subcutaneous flank. ............................................................................................... 71
Figure 3-7 Representative time-lapse images showing the lack of gelation with EAKIIH6
in vivo. .............................................................................................................................. 73
Figure 3-8 Stability of EAK16-II/EAKIIH6 in BALB/c mouse footpads. ....................... 77
Figure 3-9 Live animal imaging of membrane-immobilized IgG in 4T1 tumors. ............ 81
Figure 3-10 Ex vivo imaging of membrane-immobilized IgG in B16-F10 tumors. ......... 84
Figure 4-1 Schematic depiction of acute rejection of allograft. ........................................ 92
Figure 4-2 Attenuation of T cell activity using anti-dAPCs membrane. .......................... 95
Figure 4-3 Procedures of mouse skin transplantation. ...................................................... 97
Figure 4-4 Stability of the antibody display system in BALB/c mouse footpads. ......... 104
Figure 4-5 Real time monitoring of antibody localization in vivo. ................................ 106
Figure 4-6 Real time stability of antibody display system at the graft site..................... 108
Figure 4-7 Detection of I-Ad dAPCs in draining lymph nodes by flow cytometry. ....... 112
Figure 4-8 Concentration of IFN-γ and IL-10 produced by recipient C57BL/6 mouse
splenic T cells cultured with naïve BALB/c APCs. ........................................................ 115
Figure 5-1 Non-precipitation and self-sorting of EAKIIH6. .......................................... 131
Figure 5-2 Conformational properties of EAKIIH6 aggregates. .................................... 134
Figure 5-3 Co-assembly efficiency as a function of molar ratios of EAK16-II to
histidinylated peptides. ................................................................................................... 137
Figure 5-4 Amino acid sequences and conformations of His-tagged peptides studied. . 138
Figure 5-5 Detection of accessible His-tags in co-assemblies in vitro. .......................... 141

xv

Figure 5-6 In vivo real-time detection of His-tags in formulations with diluted EAKIIH6.
......................................................................................................................................... 148
Figure 5-7 Proposed pathways of EAKIIH6 incorporation into EAK16-II fibrils. ........ 152

xvi

LIST OF ABBREVIATIONS
APC

antigen presenting cell

Chicken-IgG800

DyLight 800 conjugated goat anti-chicken IgG

ADSA-P

axisymmetric drop shape analysis-profile

AFM

atomic force microscopy

αH6-IgG

Anti-His-tag antibodies

αH6-IgGFITC

fluorescein conjugated Rabbit anti-His-tag polyclonal antibody

αI-Ad IgG

anti-I-Ad IgG

ALK

osteogeic growth peptide ALKRQGRTLYGF

Rabbit-IgG800

DyLight 800 conjugated goat anti-rabbit IgG

αTGF-β IgG

anti-TGF-β IgG

ATR

attenuated total reflectance

AUC

area under the curve

BMHP

bone marrow homing peptides

BSA

bovine serum albumin

CD

circular dichroism

CSA

cyclosporine A

CSAC

critical self-assembly concentration

CTL

cytotoxic T cell

CTLA-4

cytotoxic T lymphocyte antigen-4

dAPC

donor antigen presenting cell

DAR16-IV

peptide ADADADADARARARAR

xvii

dDC

dermal dendritic cell

DGR

osteopontin cell adhesion motif DGRGDSVAYG

dLC

donor Langerhans’ cell

EAK16-I

peptide AEAKAEAKAEAKAEAK

EAK16-II

peptide AEAEAKAKAEAEAKAK

EAK16-IV

peptide AEAEAEAEAKAKAKAK

EAKIIH6

peptide AEAEAKAKAEAEAKAKHHHHHH

EAKIVH6

peptide AEAEAEAEAKAKAKAKHHHHHH

EAR8-II

peptide AEAEARAR

ECM

extracellular matrix

ELISA

enzyme linked immunosorbent assay

Fab

fragment antigen-binding

FAP

fluorogen-activating protein

FBS

fetal bovine serum

Fc

fragment crystallizable region

FEFK16-II

peptide FEFEFKFKFEFEFKFK

FI

fluorescent intensity

FKFE12-I

peptide FKFEFKFEFKFE

FKFE16-I

peptide FKFEFKFEFKFEFKFE

FKFE8-I

peptide FKFEFKFE

FT-IR

fourier-transformed infrared

hAPC

host antigent presenting cell

HUVEC

human umbilical vein endothelial cells

xviii

IFN-γ

interferon γ

Ig

immunoglobulin

IGF-1

insulin growth factor-1

IgG800

DyLight 800 conjugated goat anti-chicken IgG

IL-10

interleukin 10

IL-2R

IL-2 receptor

InitF

initial fluorescence

KLDL12-I

peptide KLDLKLDLKLDL

mAb

monoclonal antibodies

MHC

major histocompatibility complexes

MHC-II

class II major histocompatibility complexes

MW

molecular weights

NIR

near infrared

NMR

nuclear magnetic resonance

pAG

protein A/G

PAGE

polyacrylamide electrophoresis

PBS

phosphate buffering solution

PD1

programmed cell death protein 1

PEG

polyethylene glycol

PET

polyethylene terepthlate

PGR

RGD binding sequence PRGDSGYRGDS

PLGA

poly(lactic-co-glycolic acid)

PVA

polyvinyl alcohol

xix

Q-11

peptide QQKFQFQFEQQ

RADA16-I

peptide RADARADARADARADA

RADA16-II

peptide RARADADARARADADA

RADA16-IV

peptide RARARARADADADADA

RGD

RGD peptide

SDS-PAGE

sodium dodecyl sulfate polyacrylamide electrophoresis

SEM

scanning electron microscopy

TAA

tumor-associated antigen

Treg

regulatory T cells

TGF-β

transforming growth factor β

TGF-β1

transforming growth factor β1

TNF-α

tumor necrosis factor α

VHAH6

peptide VHASHAVHAAHAVHAHHHHHH

Single amino acid codes
A

alanine

I

isoleucine

R

arginine

C

cysteine

K

lysine

S

serine

D

aspartic acid

L

leucine

T

threonine

E

glutamic acid

M methionine

V

valine

F

phenylalanine

N

asparagine

W tryptophan

G

glycine

P

proline

Y

H

hisitidine

Q

glutamine

xx

tyrosine

CHAPTER 1
Introduction
Statement of the problem
Immunity is mediated through cell-cell interactions and various cytokines. Antigen
presenting cells (APCs) process and display antigenic peptide on the surface through
major histocompatibility complexes (MHC) (1). Helper CD4 T cells are activated by
APCs via binding of T cell receptor (TCR) to MHC and binding of CD28 to
costimulatory molecules (i.e. B7) (1).

Immune responses include production of

immunoglobulin (Ig) and activation of CD8 cytotoxic T cells and macrophages, which
collectively eliminate the target pathogens (1).
The human immune system maintains a delicate balance such that non-self pathogens
are eliminated but self-molecules are tolerated. Many diseases, such as autoimmune
diseases and cancer, are associated with abnormal changes in polarization of immune
cells. For example, infiltrating regulatory T cells (Treg) in tumors mediate immune
tolerance to cancer cells (2-4). Treg cells produce immune inhibitory cytokines, e.g. IL10 and transforming growth factor β (TGF-β), to suppress CD8 T cells and myeloid cells.
Treg cells also down-regulate the activity of APCs through surface cytotoxic T
lymphocyte antigen-4 (CTLA-4) (2, 5). In Crohn’s disease, extended lifespan of T cells
as well as increased level of pro-inflammatory cytokines such as interferon γ (IFN-γ) and
tumor necrosis factor α (TNF-α) induces and perpetuates chronic inflammation (6). In
the case of transplantation, activation of host T cells would lead to rejection of the
allografts; therefore, the host immune responses has to be suppressed intentionally (7).
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Immunotherapies have been explored based on the concept of immune balance (4, 811). One way to achieve immune modulation is using antibodies to block cell surface
molecules or neutralize soluble cytokines (12-14).

The emergence of hybridoma

technology (15) has made production of monoclonal antibodies (mAb) possible at the
manufacturing scale. Currently, there are 30 mAb drugs approved by FDA (Table 1-1)
with more than 400 clinical trials in progress. Antibodies could modulate the immune
activity by blocking cell surface molecules, such as CD3, CD20, IL-2 receptor (IL-2R),
CD33, CTLA-4, and programmed cell death protein 1 (PD1), or by neutralizing proinflammatory cytokines, such as TNF-α.

For instance, the affinity of CTLA-4 to B7

molecules is 20 times higher than that of CD28 to B7. The binding of CTLA-4 to B7
molecules could deliver an inhibitory signal to activated T cells, which help the tumor
escape from immune surveillance (2). Ipilimumab binds to CTLA-4 and abolishes the
competing binding of CTLA-4 to B7 molecules, which results in activation of T cells
(Figure 1-1).
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Antibody
Muromonab-CD3
Abciximab
Rituximab
Basiliximab
Daclizumab
Palivizumab
Infliximab
Trastuzumab
Gemtuzumab
Alemtuzumab
Adalimumab
Tositumomab
Efalizumab
Cetuximab
Ibritumomab
Omalizumab
Bevacizumab
Natalizumab
Ranibizumab
Panitumumab
Eculizumab
Certolizumab
Golimumab
Canakinumab
Catumaxomab
Ustekinumab
Tocilizumab
Ofatumumab
Denosumab
Belimumab
Ipilimumab
Brentuximab
Pertuzumab
Raxibacumab
AdoTrastuzumab
Obinutuzumab
Ramucirumab
Vedolizumab
Siltuximab
Secukinumab
Nivolumab
Lambrolizumab
Dinutuximab

Trade name
Orthoclone Okt3
Reopro
Rituxan
Simulect
Zenapax
Synagis
Remicade
Herceptin
Mylotarg
MabCampath
Humira
Bexxar
Raptiva
Erbitux
Zevalin
Xolair
Avastin
Tysabri
Lucentis
Vectibix
Soliris
Cimzia
Simponi
Ilaris
Removab
Stelara
Actemra
Arzerra
Prolia
Benlysta
Yervoy
Adcetris
Perjeta
Abthrax
Kadcyla
Gazyva
NA
NA
NA
NA
NA
NA
NA

Target
CD3
GPIIb/IIIaR
CD20
IL2R
IL2R
AFP
TNF-α
HER2
CD33
CD52
TNF-α
CD20
CD11a
EGFR
CD20
IgE
VEGF
α4 integrin
VEGF
EGFR
C5
TNF-α
TNF-α
IL1b
EpCAM/CD3
IL12/23
IL6R
CD20
RANK-L
BLyS
CTLA-4
CD30
HER2
PA
HER2
CD20
VEGFR2
α4β7 integrin
IL-6
IL-17a
PD1
PD1
GD2

Indication
Kidney transplant rejection
Blood clots in angioplasty
Non-Hodgkin's lymphoma
Kidney transplant rejection
Kidney transplant rejection
RSV infection
Crohn’s disease
Breast cancer
Acute myeloid leukemia
Chronic myeloid leukemia
Rheumatoid arthritis
Non-Hodgkin lymphoma
Psoriasis
Colorectal cancer
Non-Hodgkin's lymphoma
Asthma
Colorectal cancer
Multiple sclerosis
Macular degeneration
Colorectal cancer
Paroxysmal nocturnal hemoglobinuria
Crohn disease
Rheumatoid arthritis and spondylitis
Muckle-Wells syndrome
Malignant ascites
Psoriasis
Rheumatoid arthritis
Chronic lymphocytic leukemia
Bone Loss
Systemic lupus erythematosus
Metastatic melanoma
Hodgkin lymphoma
Breast Cancer
Anthrax infection
Breast cancer
Chronic lymphocytic leukemia
Gastric cancer
Ulcerative colitis, Crohn’s disease
Castleman disease
Immunosuppression
Melanoma
Melanoma
Neuroblastoma

Approval
1986
1994
1997
1998
1997
1998
1998
1998
2000
2001
2002
2003
2003
2004
2002
2003
2004
2004
2006
2006
2007
2008
2009
2009
2009
2009
2010
2009
2010
2011
2011
2011
2012
2012
2013
2013
In review
In review
In review
In review
In review
In review
In review

Table 1-1 Therapeutic mAb approved or in review. Information is up to date as of Jan
4, 2014. Adapted with permission from Janice M. Reichert Ph.D. (Editor-in-Chief, mAbs;
President, The Antibody Society). GPIIb/IIIaR: glycoprotein IIb/IIIa receptor; IL-2R: IL2 receptor; AFP: A antigenic site of the F protein in respiratory syncytial virus; TNF-α:
tumor necrosis factor alpha; HER2: human epidermal growth factor receptor 2; EGFR:
epidermal growth factor receptor; IgE: immunoglobulin E; VEGF: vascular endothelial
growth factor; C5: complement protein C5; EpCAM: epithelial cell adhesion molecule;
3

IL-6R: IL-6 receptor; RANK-L: receptor activator of nuclear factor kappa ligand; BLyS:
B lymphocyte stimulator; CTLA-4: cytotoxic T lymphocyte antigen-4; PA: protective
antigen of lethal toxin of Bacillus anthracis; VEGFR2: vascular endothelial growth factor
receptor 2; PD1: programmed cell death 1; GD2: disialoganglioside 2; RSV: Respiratory
syncytial virus.
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Figure 1-1 Therapeutic mechanism of Ipilimumab, an anti-CTLA-4 antibody.
Normally, T cells are activated after interacting with APCs via MHC-TCR and B7-CD28
(a). However, T cells also express CTLA-4, which compete for the binding of B7
molecules and transmit an inhibitory signal (b). When the CTLA-4 is blocked by
Ipilimumab (c), the activation of T cells is restored.
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One of the major obstacles of these approved mAbs therapeutics is poor distribution in
diseased tissues (16, 17). Despite their high specificity for targeted antigens, many mAbs
lack the necessary specificity at the organ/tissue level. Consequently, off-target binding
of mAbs in non-diseased tissues or bystander cells can result in severe immune related
side effects (18). For example, Ipilimumab, targeting CTLA-4, was developed to restore
the immune response to cancer cells. Nonetheless, severe side effects, such as colitis and
rash, had been reported due to the non-selective blocking of inhibitory signal of T cells in
normal tissues (19). Administration of immune suppressive antibodies, such as anti-IL2R antibodies, in transplantation management would render the patients vulnerable to
infections, or even cancer development. More importantly, this non-specific distribution
has been a great barrier to the successful development of new mAb. Teplizumab was
tested in clinical trials for Type I diabetes. Binding of Teplizumab to CD3 on T cells
leads to immune suppression. The results from clinical trials were disappointing as it
also increased the risk of infection and cancer development (20).
To mitigate these side effects, mAbs can be administrated to the local immune milieu
(21). Intratumoral injection is an example of such efforts. However, researchers have
shown that mAbs can diffuse away quickly from tumor due to elevated interstitial fluid
pressure (22) or may be rapidly cleared by Fc receptor mediated endocytosis and
lymphatic drainage (23). These barriers continue to impede the long-term success of
mAb therapeutic development and drive the necessity for the strategic design of an
effective mAb delivery system to improve the clinical outcomes of mAb therapeutics.
The goal of my project is to develop a versatile system that could retain antibodies in the
diseased tissue.
6

Significance
The global revenue of mAbs reached $44.6 billion in 2011, and it is projected to rise at an
annual growth rate of 5.3% to about $58 billion in 2016 (24). Of the 30 mAbs approved
and several potential ones in development, 25 exert their therapeutic effects by
modulating immune activity via neutralizing cytokines or binding to cell surface
molecules (Table 1-1).

The advantageous efficacy of mAbs lies in their excellent

specificity and high affinity towards their cognate antigens. However, the therapeutic
outcomes are compromised due to systemic exposure (12, 13, 16, 18). This undesirable
exposure to cells other than target cells causes severe side effects. To minimize systemic
exposure, there is a great unmet need for efficient antibody delivery systems.
We have developed an antibody delivery system that could stably display antibodies at
the site of injection for at least 5 days in vivo. In this system, two peptides, EAK16-II
and EAKIIH6, co-assemble into a stable His-tagged membrane in situ. His-tags are
recognized and bound by anti-His-tag antibodies (dissociation constant (Kd) ~ 2 × 10-9 M,
(25)), which also provide Fc domains to protein A/G (pAG).

Hexavalent pAG could

interact non-covalently with Fc domains of both anti-His-tag antibody and therapeutic
IgG molecules with high affinity (Kd ~ 1 × 10-8 M, (26)). Theoretically, any antibody
(IgG) could be loaded onto the His-tags via its Fc domain. The stimuli-responsiveness of
self-assembling peptides may provide excellent patient compliance in future clinical
translation.

Peptides and proteins can be mixed and injected using syringes. Upon
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exposure to physiological salts, the peptides spontaneously self-assemble in situ to
display antibodies.
The His-tagged membrane is considered to be biocompatible. Studies have shown that
self-assembling peptides are not immunogenic, inflammatory, or cytotoxic. The Zhang
group had tested the biocompatibility of EAK16-II in rabbits and rats. No detectable
immune response was elicited and no significant titers of antibodies were produced (27,
28).

Histology studied revealed that no apparent inflammation or any structural

abnormalities were observed in the muscle tissue where the injection occurred. Our
studies had shown that the EAK16-II/EAKIIH6 membrane was not toxic to epithelial
cells and T cells (unpublished data). It was found that EAK16-II has similar sequence to
intermediate neural filament H, L, and M proteins, which may mark them as “selfmolecules” (29).
After administration, we expect the system would degrade eventually. His-tagged
membrane may first break down into small fragments, which may be taken up by residing
macrophages or drained into the lymphatic system. Peptides in macrophage could be
processed and degraded in lyso-endosomal compartments by enzymatic cleavage. More
importantly, single peptide, measures about 6 nm × 1 nm, might further dissociate from
these fragments and be cleared by renal filtration, which has a size cut off of 10 nm (30).
This antibody display system is highly versatile. First, any IgG molecules may be
displayed via the non-covalent pAG-Fc interactions. The antibody display system can be
transferred and studied in different disease models using antibodies targeting different
antigens. Second, coordination bonds between Histidines and metal ions (e.g. Nickel)
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can be employed to load other therapeutic regimens. For example, the Meng lab had
developed and characterized poly(lactic-co-glycolic acid) (PLGA)-polyvinyl alcohol
(PVA) nanoparticles modified with Nickel-lipids, which provide Nickel ions on
nanoparticle surface.

Therapeutic agents may be encapsulated into nickel coated

nanoparticles, which would be stably loaded onto the His-tagged EAK16-II/EAKIIH6
membrane (data unpublished). Third, interactions of streptavidin and biotin may be
employed as linking mechanisms. EAK16-II may be functionalized with a biotin in the
C-terminal.

Using streptavidin as a linker, biotinylated antibodies might be displayed

through the non-covalent biotin-streptavidin interactions. Fourth, His-tagged peptides
co-assemble with the parent peptides to form His-tagged membranes in situ. Thus, other
self-assembling peptides may be explored to form the His-tagged membrane, which allow
us to further optimize the performance of antibody display system in different disease
models by selecting different self-assembling peptides.
Since this antibody display system utilizes non-covalent interactions between proteins,
antibodies displayed are unlikely to denature compared to conjugation. The antigen
binding domains (Fab) are oriented away from the EAK16-II/EAKIIH6 membrane for
optimal binding. When multivalent antigens or cell surface antigens are targeted, the
apparent binding affinity (avidity) will be increased exponentially as the binding may
occur at multiple sites simultaneously and synergistically. For example, single-chain
antibody fragments (scFv), which has only one binding domain, have a Kd of 3.2 × 10-7
M; the Kd of the full antibody (two binding domains) plummets to 5 × 10-10 M (31).
Cells carry a few hundred to a few thousand copies of a certain surface marker (1),
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therefore, once bound, the target cell is unlikely to desorb due to this multivalent
interaction mode (Figure 1-2).

Figure 1-2 Proposed multivalent interactions between displayed antibodies and
target cell.
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In our design, two peptides, EAK16-II and EAKIIH6, co-assemble into fibrous
membrane in situ, with the latter providing antibody loading sites. An advantage of this
approach is that the functional motif is structurally decoupled from the assembling
domain, thereby allowing adjustment of the density of functional motif by simply
changing the ratio of the two.

Specifically, the dose of antibody displayed could be

tuned by the His-tag density. Antibodies are mounted onto His-tags via linker proteins.
The theoretical maximal antibody dose is determined by the steric effect of IgG
molecules. Hydrodynamic dimensions of the antibody were about 25 nm × 4 nm when
assuming an ellipsoidal shape (32). According to Ma et al, the distance of two Fab
domains is 16.9 nm (33), hence, only one αH6-IgG would be bound per 16.9 nm of fibrils.
In other words, even there are several His-tags present, only one His-tag will be
apparently accessible per 16.9 nm fibril. Further reducing the His-tag density (< 1 Histag per 17 nm) would render all His-tags accessible to αH6-IgG, allowing precise
adjustment of the dose of antibodies displayed.
In addition, characterization of the peptide co-assembly has broader impact in
functionalization of self-assembling peptides and pathogenesis of β-amyloids in
neurodegenerative diseases. Biologically active motifs have been conjugated to selfassembling peptide to promote the proliferation and differentiation of cells (34). Like
EAKIIH6, these functionalized peptides generally lack self-assembling capacity;
therefore, parent peptides are usually added to form the peptide co-assembly and display
the functional motifs. Our data has demonstrated that this strategy (peptide co-assembly)
is feasible and the density of the functional motifs can be tuned by changing the ratio of
two peptides. EAKIIH6 adopts α-helix conformation and could not self-assemble into
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ordered β-sheet structures. At the presence of parent peptide β-sheets, EAKIIH6 is able
to co-assemble possibly by adopting a β-strand conformation as suggested by the “dock
and lock” theory (35). This template guided conformational conversion may also exist in
the formation of β-amyloids. Native proteins may unfold and become stabilized in βstrand conformation when there are existing β-sheet templates.
In summary, a biocompatible, versatile, and injectable antibody display system have
been developed and characterized. The driving motivation is to improve the clinical
outcomes of immune-modulatory mAb by minimizing systemic exposure. Immobilized
antibodies would neutralize soluble antigens, such as TGF-β and TNF-α, or interact with
immune cells directly by binding to cell surface molecules, such as CTLA-4 and MHC.
Antibodies will stay at the site of injection for an extended period of time; hence,
undesirable effects to non-targeted cells would be minimized.

Antibody display system
The use of self-assembling peptides to construct functional biomaterials has been
extensively studied in recent years (36, 37). By manipulating the peptide composition
(charge, hydrophobicity, and/or number of repeats), functional biomaterials can be
prepared from simple monomers (37, 38). A detailed review on ionic complementary
self-assembling peptides is provided in chapter 2 of this dissertation.

The self-

assembling β-sheet peptide, EAK16-II, represents one of these kinds. EAK16-II
(sequence: AEAEAKAKAEAEAKAK, E: glutamate; A: alanine; K: lysine) was
discovered in a yeast protein, which binds to left-handed DNA (Z-DNA) (39). EAK16-II
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is composed of alternating hydrophobic (alanine) and hydrophilic (glutamic acid and
lysine) amino acids. At neutral pH, EAK16-II adopts a β-strand conformation with
hydrophobic alanine side chains at one side and hydrophilic glutamate and lysine side
chains on the other side. These β-strands align in an anti-parallel manner and form
amphiphilic β-sheets stabilized by hydrogen bonding among peptide backbones. The
addition of salts will effectively screen ionic charges. Therefore, upon salt exposure (>
20 mM), these β-sheets laminate into nanofibers by inter-sheet hydrogen bonding and
electrostatic interactions and inter-sheet hydrophobic interactions (Figure 1-3). This is
thermodynamically favorable because water molecules hydrating hydrophobic alanines
are released (entropy increase). The physical crosslinking of these nanofibers produces a
stable gel-like structure (40, 41). Replacing alanine, glutamate, or lysine with similar
amino acids does not change the self-assembling capacity (42), and therefore, a series of
self-assembling β-sheet peptides have been designed and characterized including
RADA16-II (sequence: (RARADADA)2, R: arginine; D: aspartate) (43).

Figure 1-3 Schematic depiction of the self-assembling of EAK16-II. Figure adapted
with permissions from reference (38) and (42).
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Self-assembling peptides have been widely investigated as delivery systems.
Antibodies and growth factors are all capable of being loaded and delivered using the gel
in situ. The molecular weight and surface charge of the macromolecules and nanofiber
density of the gel dictate the release profile (44-46).

Alternatively, short bioactive

peptides were conjugated to the C-termini by peptide bonds (47-49). Although the
addition of functional group impaired the self-assembling capacity, the modified peptides
could co-assemble with the parent peptides to display the functional motifs (47-49).
These studies, among others, confirm the feasibility of using self-assembling peptides for
antibody delivery.
To utilize EAK16-II for local delivery of IgG molecules, several possible strategies
can be considered. Firstly, IgG can be encapsulated into the fibrous networks nonspecifically (44). However, orientation of the IgG cannot be guaranteed. In addition, IgG
will still be cleared rapidly after they diffuse out of the EAK16-II structure. The second
strategy is to covalently conjugate the IgG molecules onto EAK16-II either by chemical
synthesis or protein expression. Besides the tedious efforts involved in conjugation, the
bulky IgG may completely abolish the self-assembling capacity (34). The third strategy
is tethering IgG onto the EAK16-II membrane by non-covalent but specific interactions;
however, there are no mounting sites on EAK16-II to serve for this purpose. In order to
design a versatile platform for local delivery of mAb, we functionalized EAK16-II with a
His-tag

appended

at

the

C-terminus,

i.e.

EAKIIH6

(sequence:

AEAEAKAKAEAEAKAK-HHHHHH, H: histidines) (50) (Figure 1-4). EAK16-II and
EAKIIH6 co-assemble into an insoluble fibrous network with the His-tag accessible.
Anti-His-tag antibodies (αH6-IgG) and protein A/G (pAG) are utilized as intermediate
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adaptors (Figure 1-5). αH6-IgG binds to the His-tags with its Fab domains, and provides
Fc domain for the recognition of pAG. pAG has six binding sites for Fc domains (51).
Therefore, a second IgG can be displayed via its Fc domain, and can orient the Fab
domains away from the surface because of the steric effects of IgG molecules. IgG
molecules (MW 150 kDa) are much larger than pAG (MW 50 kDa).

When a second

IgG molecule approaches the pAG already bound to αH6-IgG, it would locate itself away
from αH6-IgG as far as possible to minimize steric repulsion. This favorable orientation
of Fab domains would facilitate the binding to cognate antigens. Peptides and antibodies
can be injected as a solution into physiological conditions to display IgG as the peptides
self-assemble in situ. Antibodies displayed are unlikely to denature due to a lack of
covalent conjugation. We also envision that the dose of antibodies can be adjusted by
tuning the number of available loading sites, i.e. His-tags. Our long term goal is to
develop this antibody display system as a versatile platform for immune modulation. The
system was shown to remain stable in vitro for 7 days in PBS.

When anti-CD4

antibodies were mounted, CD4 T cells were captured from a mixed population of
lymphocytes (52). However, the performance has not been tested and validated in vivo.
How the two peptides co-assemble warrants closer examination.
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Figure 1-4 Peptide sequence and chemical structures of EAK16-II and EAKIIH6.
Schematic illustration was drawn in Molecular Operating Environment with peptides in
extended form. Red: oxygen; blue: amine: gray: carbon; light gray: hydrogen.
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Figure 1-5 Schematic illustration of the peptide co-assembly and antibody display
system. EAK16-II and EAKIIH6 co-assemble into a fibrous structure to provide
accessible His-tags. αH6-IgG binds to those His-tags and pAG binds to the Fc of αH6IgG. Through Fc-pAG interactions, any IgG molecules can be loaded. Molecular models
of IgG were generated from the x-ray structure of an IgG2a antibody (PDB entry 1IGT
(53)) using Jmol.
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A prototype formulation had been developed for proof-of-concept studies based on
pilot experiments. EAK16-II is mixed with EAKIIH6 at a molar ratio of 4:1. In a second
vial, αH6-IgG, therapeutic IgG, and pAG are mixed at a molar ratio of 2:2:1 to form the
αH6-IgG/pAG/therapeutic IgG complexes through Fc-pAG interactions.

The molar

ratios of EAK16-II/EAKIIH6/αH6-IgG/pAG/therapeutic IgG are 9292:2273:2:2:1 and the
molar ratio of His’s-tag to αH6-IgG is 1136:1. These two vials are withdrawn into the
same syringe and injected immediately. The rationale for excessive self-assembling
peptides is that all antibodies would be displayed, which is proved to be true after 2 h
incubation in vitro (Figure 3-3, lane II). In this dissertation, The performance of this
formulation had been investigated in vitro and in vivo.

Component
EAK16-II
EAKIIH6

αH6-IgG
Therapeutic
IgG
pAG

M.W.
(Da)
1656
2480
150,000

Concentration
(µg/µL)
5
7.5
0.2

Amount used
(µL)
20
5
10

Moles used
(µmol)
0.06
0.015
1.33 × 10-5

Molar
ratio
9292
2273
2

150,000
50,000

0.2
0.25

10
1.5

1.33 × 10-5
6.5 × 10-6

2
1

Table 1-2 Stoichiometry of the antibody display system.
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Project overview
The purpose of my dissertation work is to demonstrate the feasibility and performance of
antibody display system (EAK16-II/EAKIIH6/αH6-IgG/pAG/therapeutic IgG).

The

central hypothesis of this project is that immune activity can be modulated through
antibodies displayed on in situ forming peptide co-assembly. To test this hypothesis,
three specific aims were proposed and studied.
In aim 1, proof-of-concept characterization of the antibody display system was
performed (chapter 3). Our gel electrophoresis data demonstrated that antibodies are
displayed onto the His-tags specifically through the linker proteins, αH6-IgG and pAG.
Under scanning electronic microscopy (SEM), the IgG-pAG complexes were found to be
evenly distributed on EAK16-II/EAKIIH6 fibrils. The dimensions of these complexes
indicate most His-tags display one therapeutic IgG molecule. Using TGF-β as the model
antigen, the anti-TGF-β antibodies displayed remained biologically active, and were able
to bind to its cognate antigen from three different sources in two experimental settings.
Upon administration into mice subcutaneously, the self-assembling peptides coassembled into stable His-tagged membrane up to 11 days locally. More importantly, the
antibody display system could retain a fluorescent dye labeled IgG in two epithelial
tumors in vivo.

IgG co-administrated with the system were found to remain in 4T1

mouse mammary tumors for up to 120 h, while free IgG was cleared within the first 24 h.
Decreased clearance was also found in B16 melanoma established in mouse footpads. In
addition, the system was able to deliver antibodies to the entire tumor tissue. These
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studies prove that the antibody display system is effective in retaining antibodies locally
in vivo.
In aim 2, the biological performance of the antibody display system to modulate
immune activity was investigated in a mouse skin transplantation model (chapter 4). In
this model, host T cells are activated by direct allorecognition of emigrating donor
antigen presenting cells (dAPCs) (7, 54). These host T cells will mediate acute rejection
shortly after the surgery, which dictates outcome of surgery. The working hypothesis is
that displayed anti-dAPC antibodies can impede the trafficking of dAPCs to attenuate
systemic T cell response. The EAK16-II/EAKIIH6 membranes loaded with antibodies
were found to remain underneath normal and grafted skins for up to 6 days. dAPCs were
targeted using an antibody that binds to the MHC-II molecule expressed exclusively by
donor cells. In mice treated with the anti-dAPC membrane, fewer dAPCs were found in
host draining lymph nodes.

T cells from these recipient mice produced lower

concentrations of IFN-γ after being cultured ex vivo with dAPCs. These data suggest that
the antibody display system has the potential to alter the immune activity in vivo.
In aim 3, we sought to understand the EAK16-II/EAKIIH6 co-assembly (chapter 5).
The working hypothesis is that EAKIIH6 is incorporated into the peptide co-assembly by
aligning with EAK16-II β-sheets. We have experimentally investigated the peptide coassembly (parent peptide and functionalized peptide).

Native gel electrophoresis

indicates that EAKIIH6 self-sorted into high molecular weight aggregates without
EAK16-II. However, the EAKIIH6 aggregates contained a mixture of α-helices and βstrands instead of ordered β-sheets structures suggested by FT-IR and circular dichroism
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(CD) studies. The self-sorting of EAKIIH6 was inhibited by the parent peptide in a
concentration dependent manner. Comparing the co-assembly efficiency of EAKIIH6 to
two control peptides implies that EAKIIH6 adopted β-strand conformation and aligned
with existing amphiphilic EAK16-II β-sheets for incorporation. Injecting solutions of
EAK16-II and EAKIIH6 subcutaneously rendered His-tags detectable in live mice for at
least 312 h despite at a diluted concentration for EAKIIH6. It was also found that the
accessibility of His-tags depended on the ratio of the two both in vitro and in vivo. These
studies demonstrated that EAKIIH6 co-assembles with EAK16-II and the His-tag density
is tunable by changing the ratio of the two.
To conclude, the central hypothesis has been validated. Antibodies could be stably
displayed onto the EAK16-II/EAKIIH6 membrane via intermediate proteins, αH6-IgG
and pAG, both in vitro and in vivo. The trafficking of dAPCs to draining lymph nodes
was impeded by the anti-dAPC membrane, which resulted in attenuated host T cell
activity. EAKIIH6 was incorporated into the EAK16-II β-sheets and the density of Histag could be tuned by changing the ratio of the peptides. These data indicate that the
antibody display system is effective and promising. It can be utilized as a local antibody
delivery system for antibodies targeting soluble antigens as well as an in situ forming
membrane/surface to display antibodies targeting cell surface molecules to immobilize
target cells.
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CHAPTER 2
Design, Mechanisms, and Applications of Ionic Complementary β-sheet
Self-Assembling Peptides
Abstract
Ionic complementary β-sheet self-assembling peptides represent a major class of
biomaterials in tissue engineering and drug delivery. Upon exposure to stimuli, these
peptides self-assemble into nanofibers, stabilized by H-bonding, electrostatic interactions,
and hydrophobic interactions involving both the peptide backbones and side chains. This
provides a “bottom-up” approach in designing nanoscale biomaterials. By manipulating
the peptide composition and concentration, distinctive macroscopic structures can be
obtained for different applications. These peptides offer advantages of biocompatibility
and stimuli-responsiveness. In this chapter, the design, mechanisms, and applications of
self-assembling ionic complementary peptides are reviewed.

Introduction
Molecular self-assembly refers to the spontaneous assembly of molecules into highly
ordered structures through non-covalent interactions, such as H-bonding, hydrophobic
interactions, and electrostatic interactions (38). It is a sophisticated and delicate balance
both thermodynamically and kinetically.

Molecular self-assembly serves as a great

“bottom-up” approach to design and develop nanoscale biomaterials for tissue
engineering and regeneration, cell culture, and drug delivery (36, 55).
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Ionic

complementary β-sheet based self-assembling peptides represent one of these kinds.
These self-assembling peptides share a common sequence feature (XZXZ)n, wherein X is
a hydrophobic amino acid and Z is a hydrophilic amino acid (37). EAK16-II (sequence:
AEAEAKAKAEAEAKAK; A: alanine; E: glutamic acid; K: lysine), a natural sequence
in Zuotin, is the first ionic complementary self-assembling peptide discovered (56-58).
Thereafter, a series of self-assembling peptides have been developed by manipulating the
sequence, amino acid residues, and number of repeats in EAK16-II. These peptides selfassemble into three dimensional fibrillar networks in response to stimuli. The selfassembly is determined by many factors, such as peptide concentration, salt, pH, and
temperature. However, no conclusive mechanism and process of self-assembly have
been reported.
Short self-assembling peptides offer several advantages. Unlike proteins, they can be
produced at a large scale through solid phase peptide synthesis, and composition can be
modified easily.

They are considered as non-immunogenic insofar as no high titer

antibodies have been detected in animal studies (27, 28). Therefore, explosive effects
have been invested to develop β-sheet based self-assembling peptides for a variety of
purposes.
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Self-assembly of ionic complementary peptides
Rational design of self-assembling peptides
EAK16-II has alternating hydrophobic amino acid residues and hydrophilic amino acid
residues.

When β-strand conformation is adopted, EAK16-II has a distinctive

amphiphilic pattern with all hydrophobic alanine side chains on one side and all
hydrophilic lysine and glutamate side chains on the other side (Figure 2-1). At neutral
pH, glutamic acid is deprotonated (pKa = 4.2) and lysine is protonated (pKa = 10.7).
Therefore, EAK16-II has a characteristic charge pattern of “--++--++”. Shortly after the
discovery of EAK16-II, a series of self-assembling peptides have been designed by
systematically modifying the order, number, and type of amino acid residues (59) (Table
2-1).

For

example,

EAK16-I

(AEAKAEAKAEAKAEAK)

and

EAK16-IV

(AEAEAEAEAKAKAKAK) was designed by adjusting the order of amino acid residues
in EAK16-II. The RADA series were developed by replacing glutamic acid with aspartic
acid (D) and replacing lysine with arginine (R). These ionic complementary peptides
have been classified into four moduli based on charge distribution: modulus I (-+-+-+-+);
modulus II (--++--++); modulus III (---+++); modulus IV (----++++) (59). The roman
numerals indicate the number of same charge grouped together. The name also includes
information on type (single amino acid code) and total number of amino acid residues.
For example, EAK16-II consists of a total of 16 amino acid residues of glutamic acid (E),
lysine (K), and alanine (A). The charge distribution pattern is modulus II (--++--++).
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Figure 2-1 EAK16-II peptide in β-strand conformation. Red: oxygen; blue: amine;
gray: carbon; light gray: hydrogen.

Peptide
EAK16-I
EAK16-II
EAK16-IV
RADA16-I
RADA16-II
RADA16IV
FKFE8-I
FKFE12-I
FKFE16-I
FEFK16-II
DAR16-IV
KLDL12-I
EAR8-II

Sequence
AEAKAEAKAEAKAEAK
AEAEAKAKAEAEAKAK
AEAEAEAEAKAKAKAK
RADARADARADARADA
RARADADARARADADA

Charge pattern
-+-+-+-+
--++--++
----++++
-+-+-+-+
--++--++

Reference
(60)
(57)
(60)
(61)
(27)

RARARARADADADADA

----++++

(59)

FKFEFKFE
FKFEFKFEFKFE
FKFEFKFEFKFEFKFE
FEFEFKFKFEFEFKFK
ADADADADARARARAR
KLDLKLDLKLDL
AEAEARAR

+-++-+-++-+-+-+--++--++
----++++
+-+-+--++

(62)
(62)
(62)
(63)
(64)
(65)
(66)

Table 2-1 Summary of self-assembling peptides studied.
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Effect of peptide composition on self-assembly
The peptide composition, i.e. order, number, and type of amino acid residues, is critical to
the self-assembling capacity. Caplan et al studied the effect of peptide composition on
self-assembly

by

systematically

(FKFEFKFEFKFE) (62).

varying

the

composition

of

FKFE12-I

Specifically, the authors investigated how different

hydrophobic amino acid residues and number of repeats affect minimal salt concentration
(critical coagulation concentration) needed to induce self-assembly (gelation).

The

gelation was monitored by rheological studies. Increasing the hydrophobicity of the
nonpolar residues reduced the salt concentration required for self-assembly.

It was

postulated that self-assembly is favored because higher hydrophobicity produced higher
entropic compensation than being unassembled. It has also been reported that alaninecontaining amphiphilic peptides (such as EAK) require at least sixteen-mer peptides for
salt-induced stable matrix formation.

By contrast, leucine-containing amphiphilic

peptides (such as ELK) form salt-induced stable matrices from eight-mer peptides (61).
Self-assembly does not require the same hydrophobic residues throughout the peptide.
Wang et al replaced some or all of the phenylalanine (F) in FEFK16-II
(FEFEFKFKFEFEFKFK) with different amino acids (Table 2-2) (63). The steric effects
did affect the formation of matrix when different sizes of hydrophobic side chains could
not accommodate each other (Figure 2-2). However, hydrophobic side chains would fit
with each other by sliding when hydrophobic residues were located in a certain pattern.
For example, self-assembly was preserved when large hydrophobic residues were
distributed in the middle or the ends.
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Table 2-2 Sequences of the amphiphilic peptides studied. Adapted with permission
from reference (63).
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Figure 2-2 Schematic representation of cooperative hydrophobic interactions among
hydrophobic residues of different sizes. Peptide 81 and 82a were able to self-assemble
because hydrophobic side chains could accommodate with each other. The self-assembly
of peptide 83 was abolished as hydrophobic interactions were disrupted. Adapted with
permission from reference (63).
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Charge distribution also plays a role in self-assembly. The self-assembly of three
EAK16 peptides, namely, EAK16-I, EAK16-II and EAK16-IV, had been investigated by
AFM and surface tension measurements (60, 67). At neutral pH, EAK16-I and EAK16-II
adopted a β-sheet conformation and formed fibrillar structure. However, EAK16-IV
favored a β-turn conformation and formed globular structure. EAK16-IV has a charge
pattern of “----++++”, therefore, the peptide may bend (β-turn) due to intramolecular
electrostatic interactions (67). In addition, peptides have a higher propensity to selfassemble when peptides are electrically neutral (68). This explains why higher salt
concentration was needed for assembly when glutamic acids were replaced by glutamine
(63).

The net positive charges imposed by lysine have to be screened by higher

concentration of salts.
The peptide length exerts a biphasic effect on self-assembly. For example, FKFE12-I
requires lowest concentration of salt for assembly while FKFE8-I and FKFE16-I require
a higher salt concentration (62). Self-assembly is a delicate thermodynamic balance.
Increasing the length of peptide may strengthen the intermolecular interactions as the
number/extent of H-bonding, electrostatic interactions, and/or hydrophobic interactions
increase (enthalpy). However, the entropy loss contradicts these as the peptide has to
adopt a certain conformation during assembly.
Using chiral counterpart D-amino acids does not abolish the self-assembly. Since the
D-peptide cannot be recognized by natural proteases, self-assembling peptides of Damino acids may produce more stable scaffolds (69, 70).
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Effect of salts on self-assembly
Salts trigger self-assembly by screening repulsive net charges of peptides. Hong et al
found that the self-assembly of EAK16-II did not strongly depend on the presence of
NaCl at higher peptide concentration (>0.3 mg/mL) (71). However, the dimensions of
self-assembled nanofibers appeared to be dependent on NaCl concentration at low
peptide concentrations (<0.1 mg/mL) (71). Globular assemblies were observed in the
absence of NaCl at low peptide concentration. The radius of the nanofibers increased
until NaCl reached about 20 mM.

Further increasing salt concentration resulted in

smaller nanofibers. This indicates that NaCl promotes formation of fibril at low peptide
concentration (71). Zhang and coworkers studied the effects of different salts on selfassembly of EAK16-II (57).

Monovalent cations triggered assembly formation

effectively, while divalent cations induced disordered aggregation.

The order of

effectiveness had been determined as Li+ > Na+ > K+ > Cs+, which corresponds to the
hydrated radius of the ions: 3.40 Å (Li+), 2.76 Å (Na+), 2.32 Å (K+) and 2.28 Å (Cs+). In
addition, organic cations, such as NH4+ and TrisH+, were not able to induce EAK to form
aggregates (57). However, the effects of salts on different peptides differ. Caplan et al
demonstrated that multimeric ions were more effective in triggering self-assembly of
FKFE12-I at pH 3 with the order of K3Fe(CN)6 > K2SO4 > KCl. At pH 3, FKFE12-I
carries net positive charges as glutamic acids are neutralized. The charge screening effect
is then dependent on the valence of negative ions. Hence, the role of salts in peptide
assembly warrants more examination.
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Effect of peptide concentration on self-assembly
The Chen group reported a critical self-assembly concentration (CSAC) of 0.1 mg/mL
(60 μM) for EAK16-II in pure water (71, 72).

Surface tension and dimensions of

nanostructures were determined for a wide range of peptide concentrations using
axisymmetric drop shape analysis-profile (ADSA-P) and atomic force microscopy (AFM)
respectively, which correlated with each other very well. Surface tension dropped to
minimal when the peptide self-assembled at 0.1 mg/mL. Under AFM, fibrillar networks
were observed above the CSAC, while only isolated filaments appeared at concentrations
below the CSAC. Nonetheless, whether the mica surface used in AFM had any effect on
peptide assembly remains an open question.

Effect of pH on self-assembly
Although pH affects the protonation/de-protonation state of ionizable side chains of
amino acid residues, some peptides are insensitive to pH changes. For example, EAK16II was able to self-assemble into nanofibers from pH 1.5 to 11. This is not unexpected.
In addition to the charge screening effect of salts (58), hydrogen-bonding among side
chains of glutamate and lysine could also stabilize the fibrils. Ye et al reported that
RADA16-I self-assembled into fibrillar structures in acidic pH but not in basic pH (43).
But it shall be noted that a lower concentration (0.17 mg/mL) was used and no salts were
added in Ye’s studies. On the other hand, EAK16-IV could not form fibrillar structures
at pH 7 as it adopted a β-turn conformation (67).
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Mechanism and hierarchy of self-assembly
In solution state, self-assembling peptides adopt a β-strand conformation.
hydrophobic side is caged within ordered water molecules.

The

Triggered by charge

screening effect of salts, the self-assembly is a thermodynamic process driven by entropic
release of water molecules hydrating hydrophobic amino acid residues. Increasing the
hydrophobicity of amino acid residues elevates the self-assembling propensity. Zhang
and co-workers proposed that peptides align with each other in an anti-parallel manner to
form amphiphilic β-sheets. These β-sheets are stabilized by inter-peptide H-bonding
involving peptide bonds. Amphiphilic β-sheets stack together and form nanofibers by
hydrophobic interactions between hydrophobic faces and H-bonding and electrostatic
interactions between hydrophilic faces (36, 38, 57) (Figure 1-3). However, dimensions of
nanofibers from AFM measurements do not support this model.

The Chen group

reported a height of about 0.5 nm, which corresponds to the height of a single layer of βsheet, for fibrils of EAK16-II formed at 0.1 mg/mL (67). Although the concentration is
relatively low compared to those used in Zhang’s studies, it does imply that the selfassembly process warrants more investigation.
Cormier and coworkers explored the structure of RADA16-I nanofibers extensively
using solid state nuclear magnetic resonance (NMR) spectroscopy (73-75). Solid state
NMR spectroscopy is extremely useful in studying structures of peptide samples as it can
pinpoint the conformation of a single amino acid residue, especially when combined with
isotope labeling (76). Indeed, the results revealed that RADA16-I peptides are aligned in
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a parallel manner when forming the β-sheets. Each peptide shifts a little for maximal
electrostatic interactions. Two amphiphilic β-sheets stack by hydrophobic interactions
and the nanofiber grows by attaching peptides at the ends of β-sheets instead of stacking
more amphiphilic β-sheets (Figure 2-3) (75).

This model correlates well with

experimental data and computational simulation. The height of nanofibers was measured
to be 1.5 nm in AFM.

Figure 2-3 Molecular model of RADA16-I assembly. Peptide backbones are rendered
as ribbons, and atoms shown for alanine (green), arginine (blue), and aspartate (red)
residues. (a) Three-dimensional representation of the RADA16-I nanofiber; (b)
orthographic projection of the hydrophilic surface of a β-sheet, highlighting the predicted
configuration of arginine and aspartate side chains; (c) orthographic projection of the
nanofiber cross section. Figure adapted with permission from reference (75). Copyright
(2013) American Chemical Society.
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Interestingly, fibrillar scaffold of ionic self-complementary peptides could reassemble
after mechanical breakage.

Hammond et al broke RADA16-I nanofibers into short

fragments with sonication. The dynamic reassembly was monitored using AFM. The
fragments were able to reassemble into nanofibers which were indistinguishable from the
original self-assembly (77, 78). Yokoi et al proposed a sliding diffusion model to explain
this dynamic reassembly phenomenon (77).

Sonication broke nanofibers into small

fragments with protruding ends, which exposed the hydrophobic alanines. Hydrophobic
interactions draw these fragments together. These fragments would then slide until a
perfect fit to minimize the exposure of hydrophobic alanines. This feature is of great
value because the self-assembly scaffold will be subject to certain mechanical disruptions
when applied in in vitro or in vivo environments. It also implies that scaffold may be preassembled in the syringe. The shear forces may break down the scaffold but it will
reassemble at the site of injection.

Applications of ionic complementary self-assembling peptides
A major concern with novel biomaterials is immunogenicity, proinflammatory, and
toxicity. Zhang et al attempted to detect antibodies against RADA16-II and EAK16-II.
Peptides were injected into rabbits alone or conjugated with other proteins. No detectable
immune response was elicited, and no significant titers of antibodies were produced (27).
It was found that these peptides have similar amino acid sequence to intermediate neural
filament H, L and M proteins (29). These sequence similarities mark them as “selfmolecules”, therefore no immune responses are stimulated. Holmes et al injected
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EAK16-II, RADA16-I, RADA16-II peptides into the rats leg muscles (28). The entire
muscle was dissected and sectioned 9 days or 5 weeks after the injections. The muscle
sections were examined for mononuclear cell infiltration and muscle fiber necrosis, i.e.
inflammation or necrosis. No apparent inflammation or any structural abnormalities were
observed in the muscles compared to those injected with saline solutions. These studies
support the notion that these self-assembling peptides are non-immunogenic and noninflammatory.
Because of the biocompatibility and stimuli responsiveness, self-assembling peptides
have been widely employed in tissue engineering and regeneration, drug delivery, and
other medical applications (42, 79, 80). Self-assembling peptides form networks
spontaneously under physiological conditions. The networks contain physically cross
linked nanofibers with a diameter of around a few nanometers and a length up to the scale
of µm (36). The pore sizes range from a few nanometers to several micrometers, which
depends on the peptide concentration. Cells or therapeutic agents are all capable of being
encapsulated into the network (81).

Tissue engineering and regeneration
The extracellular matrix (ECM) is a cross-linked network of proteins and carbohydrates,
which provide structural and biochemical support for cells (82). Soon after the discovery
of EAK16-II, Zhang and co-workers found that several types of mammalian cells could
attach to the fibrillar matrix of EAK16-II or RADA16-II (27).

Thereafter, self-

assembling peptides have been widely explored as cell scaffold in tissue engineering and
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regenerations (42, 79, 83). Although the purpose of my dissertation project is to develop
an antibody delivery system using EAK16-II, applications of self-assembling peptides in
tissue

engineering

and

regeneration

provide

important

references

regarding

functionalization, biocompatibility, and optimization. Peptides can be functionalized
with growth factors and cytokines to direct cell differentiation and growth.
Biocompatibility had been demonstrated in animals. Peptidic scaffolds could be prepared
to better mimic ECM by adjusting peptide composition and concentration.

Indeed,

RADA16-I has been commercialized as cell culture scaffolds (PuraMatrix, 3-D Matrix,
Cambridge, MA).
Sieminski et al compared the adhesion of human umbilical vein endothelial cells
(HUVEC) to four different self-assembling peptide hydrogels (65). HUVEC cultured in
RADA16-I or RADA16-II hydrogels expanded into interconnected capillary-like
networks, while HUVEC in FKFE8-I or KLDL12-I formed clusters and retained their
round shape. RADA16-I and RADA16-II hydrogels were also found to support neutrite
growth and active synapse formation when sympathetic neurons were cultured (28). In
addition, RADA16-I scaffold enhanced dopaminergic differentiation of murine
pluripotent stem cells (84).

Interestingly, KLDL12-I was able to support the ECM

production and division of chondrocyte (85). It has been reported that cells can recognize
and respond to the stiffness of substrate (86, 87), which may explain why KLDL12-I
could support chondrocyte but not HUVEC.
Akiyama and coworkers utilized RADA-I hydrogel to regenerate middle ear mucosa in
rat (88). Middle ear epithelial cells were cultured from donor rats and encapsulated in
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0.25% w/v RADA16-I hydrogel (PuraMatrix) with a density of 0.5 or 1 million/mL. The
scaffold with cells was then transplanted into recipient rats, the middle ear of which had
been surgically removed. With the RADA16-I scaffold, cells in the subepithelial lesion
retained their morphology and function.

More importantly, new epithelial and

subepithelial layers had formed (88).
Self-assembling peptides have been covalently functionalized with bioactive motifs to
enhance the proliferation and differentiation of cells. These bioactive peptide sequences
can be chemically attached via peptide bonds by solid phase synthesis. However, the
self-assembly of functionalized peptides may be compromised, which depends on the
charge and size of bioactive motif (34). To circumvent it, functionalized peptides could
be premixed the parent peptide to form the scaffold together.

Horii et al modified

RADA16-I with one of the following sequences, osteogeic growth peptide ALK
(ALKRQGRTLYGF), osteopontin cell adhesion motif DGR (DGRGDSVAYG), and
RGD binding sequence PGR (PRGDSGYRGDS) (34). The three modified peptides
(1:1:1) co-assembled with RADA16-I into a hydrogel matrix displaying the three
bioactive motif, which promoted the proliferation, differentiation and migration of
osteoblast (Figure 2-4). To enhance the adhesion of human aortic endothelial cells,
sequences in laminin 1 and collagen IV, two constituent peptides of ECM, were
conjugated to RADA16-I (47). In another example, Cunha et al attached RGD peptide
(Arg-Gly-Asp) and bone marrow homing peptides (BMHP) to RADA16-I (48). Neural
stem cells proliferated and differentiated in the peptidic scaffold.
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Figure 2-4 Molecular models of functionalized peptides and peptide co-assembly.
Functionalized peptides (a) co-assemble with the parent peptide to display biological
motifs (b). Adapted with permission from reference (34).
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Stevenson et al investigated the effect of stiffness and binding site density on
microvascular formation (89). The ratio of two self-assembling peptides (FKFE8-1 and
RGD-FKFE8-I) was adjusted to generate scaffold with different stiffness and
adhesiveness. A higher content of unmodified FKFE8-I peptides produced stiffer gels
with less binding sites, in which formation of microvascular network was highly
compromised (89). Other functionalization includes RADA16-I with laminin derived
peptide IKVAV for embryonic stem cells (90), LDLK12-I with peptide KLPGWSG for
neural stem cells, and RADA16-I with heparin binding motif FHRRIKA for human
adipose stem cells (91).

Drug delivery
Zhang and coworkers studied the release profile of four proteins from RADA16-I
hydrogel scaffold (Figure 2-5) (45). A biphasic diffusion profile was observed. A rapid
initial release following Fick’s law was observed possibly due to proteins at the
peripheries and those able to diffuse via large pores (Figure 2-5b insert). After that,
diffusion deviated from the initial straight line possibly due to hindrance by small pores
and interactions. The release was sustained for about 30-50 h. The release profile
correlates well with the protein molecule weight. Diffusion constants were obtained by
modeling the initial release data with Fick’s law. Lysozyme, Trypsin inhibitor, bovine
serum albumin (BSA), and IgG which have molecular weight of 14.3 kDa, 20.1 kDa,
66.0 kDa, and 150 kDa respectively had an apparent diffusion constant of 0.5 × 10-10 m2/s,
0.32 × 10-10 m2/s, 0.24 × 10-10 m2/s, 0.07 × 10-10 m2/s accordingly (45). Kopesky et al
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studied the release kinetics of transforming growth factor β1 (TGF-β1) from KLDL12-I
hydrogel (92). When TGF-β1 (100 ng/mL) was mixed with peptide solution (0.35% w/v,
50 µL) prior to gelation, over 85% TGF-β1 was encapsulated, compared to 17% for
agarose gel. After 21 days of release, KLDL12-I hydrogel released 44% of TGF-β1
while agarose gel had released 82%. The release profile could be adjusted by changing
peptide concentration.

Forming hydrogels at higher peptide concentration produces

denser networks with smaller pores, which retard and reduce the release (45).
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Figure 2-5 Graphic representation and release profiles of lysozyme, trypsin
inhibitor, BSA, and IgG in 1% (w/v) RADA16-I hydrogels. Four proteins (a) with
different sizes were studied for their release (b) from RADA16-I hydrogels. Inserted is
protein release plotted as a function of the square root of time showing biphasic diffusion
mechanism. Adapted with permission from reference (45). Copyright (2009) National
Academy of Science, USA.

41

Positive or negative charges can be introduced into the hydrogel to tune the release
(93). Gelain et al attached short amino acid sequence to the C-terminal of RADA16-I.
The modified peptides, RADA16-DGE and RADA16-PFS, retained the self-assembling
capacity.

RADA16-DGE formed hydrogel scaffolds with net negative charges while

RADA16-PFS assembled into networks with net positive charges at neutral pH. When
proteins carrying different charges were loaded, the release was dictated by both the
charges and molecular weights. The diffusion was highly compromised when proteins
carry opposite charges to the hydrogel due to attractive electrostatic interactions (93).
Other attempt includes using a double layer hydrogel of two different self-assembling
peptides for controlled release of human antibodies. Koutsopoulos et al formulated an
“onion-like” hydrogel with RADA16-I as the inner core and KLDL12-I as the outside
shell (94). Antibodies were loaded into the inner RADA16-I gel and then coated with
KLDL12-I hydrogel. Extended release for over 3 months was demonstrated because of
the different density and chemical properties between RADA16-I and KLDL-12
hydrogels.
Besides direct encapsulation via non-specific encapsulation, another way to deliver
active proteins is tethering (95, 96). Both insulin growth factor-1 (IGF-1) and RADA161 were biotinylated. Biotinylated RADA16-1 and RADA16-1 at a ratio of 1:100
assembled into a hydrogel scaffold with accessible biotins. Streptavidin was premixed
with biotinylated IGF-1 at a ratio of 1:1.

Therefore, IGF-1 was loaded onto the

RADA16-1 nanofibers through the tethering of streptavidin-biotin interactions (Figure 26) (96). Sustained IGF-1 delivery was observed in rat myocardium for 28 days, and cell
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implantation efficacy was improved (96). Similar approach was demonstrated using the
self-assembling peptide KLDL12-1 (95).

Figure 2-6 Tethering of biotinylated IGF-1 to biotinylated self-assembling peptides
via biotin-streptavidin interactions. Red dot: biotin; green square: streptavidin.
Adapted with permission from reference (96). Copyright (2006) National Academy of
Science, USA.
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Systemic delivery using the self-assembling peptide KLDL12-I has also been reported
(97). Polyethylene glycol (PEG) was conjugated to KLDL12-I through a short peptidic
linker. This modified peptide self-assembles into single layer nanofibers of 4 nm in
width and 50-400 nm in length. These nanofibers exhibited desirable properties of nontoxicity, hemocompatibility, and negligible macrophage uptake.

Effective tumor

accumulation (5% of injected dose) was observed after tail vein injection, which is
significantly higher than pegylated polymeric spherical nanoparticles of the similar size
(2.5%) (97).
Small molecules, such as lidocaine (98), flurbiprofen (98), paclitaxel (99), pirarubicin
(66), and ellipticine (100, 101), can be loaded into the hydrogels of self-assembling
peptides.

Liu et al mixed RADA16-I peptide with paclitaxel in water and found

RADA16-I peptides were able to solubilize and stabilized paclitaxel particles (99). It was
proposed that amphiphilic RADA16-I β-sheets coated paclitaxel particles by hydrophobic
interactions. The incorporation of paclitaxel particles did not compromise the gelation of
RADA16-I, although the fraction of β-strand decreased. A higher peptide concentration
led to longer release time.

Maximal in vitro anti-tumor effect was achieved when

paclitaxel was incorporated into 1% (w/v) RADA16-I hydrogels. EAR8-II (AEAEARAR)
was synthesized to deliver pirarubicin. At a peptide to drug ratio of 5:1, stable uniform
nanostructures with a diameter of 700 nm were obtained (66).
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Hemostasis
Because of their rapid stimuli-responsiveness, i.e. sol-gel transition, self-assembling
peptides have been investigated in hemostasis models (102). Wang et al measured the
time for hemostasis in a rat spinal cord transection model using RADA16-I (103). Unsonicated 50 µL 1% w/v RADA16-I solution was able to cease the bleeding in 20
seconds. Sonication treated RADA16-I took longer time as the reassembly was not
complete until 24 h later. Luo et al reported similar efficacy when D-form EAK16-I was
used in a rabbit liver wound model (104). The D-form EAK16-I (200 µL 1% w/v
solution) was able to achieve hemostasis in 20 seconds. Ions, such as K+, Na+, Ca2+, and
Mg2+ in the blood trigger the self-assembly and the resultant fibrillar network functions
as a “fishing-net” in agglutination (104).

Pathogenesis of β-amyloids
Neurodegenerative conditions, such as Alzheimer’s disease and Parkinson’s disease, are
associated with the deposition of abnormal protein aggregates, i.e. β-amyloids (105). βamyloids are well-organized β-sheets rich fibrillar structures (76), which are converted
from native proteins under pathological conditions. The pathogenesis of β-amyloids has
been extensively studied using model proteins and peptides (106-108).

The self-

assembly of ionic complementary peptides may provide insight into amyloid formation
and how to prevent such conversion. Altman et al studied the plasticity and dynamics of
a serial of EAK peptides (109). EAK12-d (AEAEAEAEAKAK, truncated from EAK16IV) exhibited pH and temperature dependent conformation transitions (β-strand to α-helix
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at elevated temperature and basic pH). However, α-helix would eventually convert back
to β-strand, indicating β-strand represents a lower energy state stabilized by extensive Hbonding, hydrophobic interactions, and electrostatic interactions (109). An intermediate
state may exist during the α-helix to β-strand reconversion as evidenced by lack of an
isodichromic point. Existing β-sheets may guide the conversion of α-helix, and resultant
β-strand will be captured and stabilized by the β-sheets template present. A similar
process may exist in β-amyloid formation. The authors further proposed that increasing
the activation energy needed for α-helix to β-strand conversion could prevent amyloid
formation. This can be achieved through molecular inhibitors that stabilize α-helix or
sequester the intermediate states.

Summary
Great advances have been achieved in understanding, designing, and utilizing ionic
complementary β-sheets based self-assembling peptides. Owing to their biocompatibility
and stimuli-responsiveness, these self-assembling peptides represent a major class of
biomaterials in tissue engineering and drug delivery. However, no definitive model of
self-assembly has been reported. Self-assembly may differ from peptide to peptide. The
relationship between molecular peptide structure and final peptide assembly requires
more scrutinization. High resolution techniques, such as solid state NMR and x-ray
crystallography, may be required to fully explore the hierarchy of peptide assembly.
Experimental evidence is required to support the hypothesis that a functionalized peptide
(e.g. ALK, DGR, and PGR (34)) can co-assemble with the parent peptide to display
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bioactive motifs. Despite these challenges, engineering of ionic complementary selfassembling peptides has tremendous potential in medical and pharmaceutical progresses.
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CHAPTER 3
Retaining Antibodies in Tumors with a Self-assembling Injectable
System
Abstract
The performance of an in situ-forming injectable membrane designed to retain antibody
molecules in vivo is described.

The system entails an aqueous mixture of peptide

amphiphiles (referred to as “EAK16-II” and “EAKIIH6”) and intermediate proteins (antiHis-tag antibody and protein A/G) through which therapeutic IgG molecules are colocalized and oriented. Scanning electron micrographs show IgG molecules localized on
the EAK16-II/EAKIIH6 membrane. IgG were captured via specific interactions and
remained biologically active in vitro. Upon administration into mice subcutaneously, the
amphiphilic peptides co-assembled into stable His-tags displaying materials locally. The
system was shown to retain in vivo a fluorescent dye-labeled IgG in two epithelial tumor
lines.

IgG co-administered with the system were found to remain in 4T1 mouse

mammary tumors for up to 120 h, while free antibody was cleared within the first 24 h.
Decreased clearance was also found in B16 melanoma established in mouse footpads.
These studies demonstrated that the immobilizing mechanism was effective in enhancing
the retention of IgG locally in vivo. The injectable system may be used to enhance the
delivery of immune modulatory antibodies in tumors.
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Introduction
Primary tumors can be exploited for the purpose of generating immunity that eliminates
metastasized cancer cells systemically (21).

Endogenous proteins released from

apoptotic or necrotic cancer cells are sources of tumor-associated antigens (TAAs).
Immunological presentation of TAAs by antigen-presenting cells (APCs) activates
tumor-specific lymphocytes in draining lymph nodes (110, 111). T and B lymphocytes
activated and expanded therein eventually migrate to populate all lymphoid organs.
Whether the responses result in eliminating or promoting the cancer systemically is
largely dependent upon the immune milieu within which APCs are immersed (112).
Most common human (and rodent) cancers impose suppressive regimes by which host
lymphocytes become tolerant of the cancer (2). Consequently, attempts have been made
to steer APCs to orchestrate lymphocytes to oppose the cancer by modulating the tumor
immune milieu. Examples of this strategy include administration of interleukin and tolllike receptor agonists into cancer lesions (113-119).

Monoclonal antibodies are an

important class of immune modulators, but studies have shown that these
macromolecules are cleared rapidly in tumors (119).
The tumor microenvironment poses barriers to the distribution and retention of IgG
molecules. Poor distribution is attributed to the high interstitial fluid pressure found in
many tumors (119). Pressure gradients originating from the necrotic center force fluids
toward the periphery of the lesion. The dense extracellular matrix in many epithelial
tumors also impedes the distribution of IgG (120). Excess collagens produced by stromal
fibroblasts slow diffusion and convection of IgG molecules.
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The poor tumor

accumulation of intravenously infused IgG inspired the use of intratumoral injection as an
alternative. It was thought that the pressure exerted by infusion syringes in tumor could
overcome the resistance, but macrophages and dendritic cells residing in tumors
efficiently remove IgG molecules via membrane-bound Fc receptors (121).
We sought to develop an injectable platform by which retention of IgG molecules in
tumors can be enhanced. We have designed an antibody display system by which IgG
molecules are localized and oriented on a co-assembly of EAK16-II and EAKIIH6, an
analogue of the former with six histidine residues (His-tag) appended at the C terminus
(50). The working model is that EAK16-II and EAKIIH6 assemble into -sheet bilayers
that laminate into fibrils with accessible His-tags. Molecular modeling suggests that the
amphiphilic repeats in EAK16-II and EAKIIH6 align in an anti-parallel -sheets from
which the histidines rise above.

In vitro, this His-tag displaying membrane remains

stable for at least 3 weeks at 37 C (50). The design exploits the specific interactions
between protein A/G (pAG) and the Fc region in IgG to orient Fab from the surface
(Figure 3-1). The functional utility of the platform has been validated in experiments in
which membranes loaded with anti-CD4 antibodies immobilize CD4+ T cells from
splenic lymphocytes in vitro (50). However, the interactions among each component
have not been examined. The in vivo assembly and stability of the system has not been
demonstrated. The current chapter presents evidence demonstrating the assembly and
stability of the system in living tumors in which near infrared (NIR) dye-conjugated IgG
were tracked optically in live animals.
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Figure 3-1 Schematic depiction of the IgG displaying system. Molecular models of
IgG were generated from the x-ray structure of an IgG2a antibody (PDB entry 1IGT (53))
using Jmol.
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Materials and Methods
Materials
The peptides EAK16-II and EAKIIH6 were custom synthesized by American Peptide
Company (Sunnyvale, CA) at greater than 90% purity. Peptides were acetylated and
amidated at the N and C termini, respectively. Peptides were reconstituted in sterile
deionized water (18.2 M at 25C) at 5 mg/mL for EAK16-II and 7.5 mg/mL for
EAKIIH6. Rabbit anti-His-tag polyclonal antibody (αH6-IgG, 0.2 mg/mL) was obtained
from AnaSpec, Inc (San Jose, CA). Recombinant protein A/G (pAG) was obtained from
Pierce Biotechnology (Rockford, IL) and reconstituted to 0.25 mg/mL in sterile deionized
water. DyLightTM 800 conjugated goat anti-rabbit IgG (Rabbit-IgG800, 1 mg/mL) was
also purchased from Pierce Biotechnology. DyLightTM 800 conjugated goat anti-chicken
IgG (Chicken-IgG800) was obtained from KPL (Gaithersburg, MD) and reconstituted to
1 mg/mL in sterile deionized water.

Transforming growth factor β (TGF-β) IgG1

antibody (clone 1D11, αTGF-β IgG, 0.2 mg/ml) were harvested from the culture medium
of 1D11 hybridoma (ATCC, Manassas, VA) and purified using the Montage® antibody
purification kit with PROSEP®-A media (Millipore, Billerica, MA). Congo red stock
solution (0.1%) was purchased from Fisher Scientific (Rochester, NY). 4T1 and B16F10 cell lines were obtained from ATCC. RPMI-1640 and fetal bovine serum (FBS)
were obtained from HyClone (Logan, Utah). Penicillin and streptomycin solutions were
purchased from Lonza (Walkersville, MD).
Mediatech (Manassas, VA).
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Trypsin/EDTA was obtained from

Sample preparations
Samples were prepared as follows unless indicated otherwise. The system is prepared by
adding a mixture of αH6-IgG (0.3 µM), pAG (0.15 µM), and a second IgG (0.3 µM) into
the peptide mixture of EAK16-II (1.3 mM) and EAKIIH6 (0.325 mM). This premixed
system self-assembles after being added into PBS in vitro or injected into mice in vivo.
Control groups were prepared without one or more components with the remaining
materials maintained at the same concentrations by substituting with sterile deionized
water.

Optical and scanning electronic microscopy
Bright field imaging was conducted as follow. Five microliters of each sample was
added into 5 µL of a diluted Congo red solution (0.01% in PBS) spotted on a glass slide
(Fisher Scientific, Waltham, MA). Images were captured immediately using a Vista
VisionTM inverted microscope (VWR, Radnor, PA) equipped with a ProgRes C3 cooled
CCD camera (Jenoptik AG, Jena, Germany). To prepare samples for scanning electron
microscopy (SEM), membranes were formed in PBS on a polyethylene terepthlate (PET)
membrane (8 m pore size), fixed in 10% formalin, and rinsed with deionized water three
times and lyophilized. Samples were mounted on double-sided carbon tape affixed to an
aluminum specimen holder. Images were captured using a Hitachi S-3400N microscope
at a working distance between 5-7 mm with a 5.0 kV accelerating voltage under vacuum
(<1 Pa). Particles appearing in images were evaluated using the software Axiovision
4.6.3. By selecting particles in the image field, the bound height and width of each
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particle were determined and these two values were averaged to generate the calculated
individual particle size. Measurements consisted of selecting all discrete particles from
three different areas. Particles from different areas have comparable average sizes (15.0
nm, 17.0 nm, and 17.6 nm) and are pooled together for further analysis, resulting in a
total of 421 particles analyzed.

Distances between two adjacent particles (on the same

fibril or different fibrils) were measured using the same software.

Sodium dodecyl sulfate polyacrylamide electrophoresis (SDS-PAGE)
In vitro prepared membranes were incubated in PBS at 37 ℃ for 24 hr and the
supernatants were analyzed using the denaturing NuPAGETM Novex® 4-12% gels (Life
Technologies, Carlsbad, CA). Proteins were visualized using the SilverQuest TM staining
kit (Life Technologies) with a reported detection limit of 0.3 ng and imaged using the
Kodak 440 Image Station (Rochester, NY).

Band intensities were quantified using

ImageJ (version 1.45s).

Antigen binding activity of immobilized antibodies
The function of IgG associated with the membrane was determined using ELISA to
measure TGF-β as a model antigen.

Membranes were formed in PBS on PET

membranes or in solution. 0.5 mL of TGF-β standard solution or culture media of B16F10 and 4T1 cells were applied to the system. Samples were either rinsed with distilled
water (3X) or centrifuged (16,000 g for 5 minutes at room temperature). Concentrations
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of TGF-β in filtrate or in supernatant were determined using the DuoSet® mouse TGF-β
kit (R&D system, Minneapolis, MN). Absorbance at 450 nm and 570 nm were measured
using a Perkin Elmer VICTOR 1420 reader (Perkin Elmer, Waltham, MA).

Mice, tumor inoculation, and imaging
Six to eight week old female (certified-virus-free) BALB/c and C57BL/6 mice were
purchased from Charles River Laboratories (Wilmington, MA) and housed in the
Duquesne University Animal Care Facility.

Animals were handled in accordance to

protocols approved by the Duquesne University Institutional Animal Care & Use
Committee. BALB/c and C57BL/6 mice were inoculated with 4T1 or B16 tumor cells,
respectively. Cell lines were cultured in RPMI-1640 (4T1) or DMEM (B16) medium,
supplemented with 10% FBS and antibiotics. Tumor cells in the exponential growth
phase (between passages 5 to 14) were harvested and suspended in sterile saline. 5×105
cells suspended (in 100 µL sterile saline) were inoculated subcutaneously in BALB/c
mouse flank (4T1) or C57BL/6 mouse footpad (B16-F10). Only tumors of equivalent
size (perpendicular diameters) were used in the studies: 0.5 × 0.5 cm for flank tumors and
0.2 × 0.2 cm for footpad imaging experiments. Recognizing that the melanin in B16
melanocytes may impede photon excitation and emission, the fluorescent intensities
obtained in this model were not directly compared to those obtained in 4T1 tumors.
Footpads were collected and stretched out on a 15 × 100 mm dish using scotch tape for
ex vivo imaging. Images were captured using an Odyssey Imager (Li-Cor, Inc., Lincoln,
NE) and measured at an intensity of 1.0 with focal distances of 3.2 mm and 3.5 mm.
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Fluorescence quantification was performed by drawing a polygon outlining the shape of
the footpad. The averaged signal of three blank footpads at each focal distance was
subtracted as background. Data reported represent fluorescence intensities averaged from
the measurement performed at each focal distance.
Anesthetization was induced using isoflurane (induction 5%, maintenance 3 %) for real
time in vivo imaging. Abdominal hairs were removed prior to scanning. Mice were
scanned prior to injection and monitored at the indicated times after injection using a
Pearl Impulse imager (Li-Cor, Inc.). All images were collected using the same threshold
and resolution (170 µm) settings. Oval-shaped regions of interest were defined at the site
of injection and the contralateral flank as background.

Fluorescence intensity was

quantified using the Impulse (2.0) software (Li-Cor, Inc.) with a standard deviation
multiplier of 10 and a search limit of 100 pixels.

Tracking retention in vivo
In vivo assembly and stability of EAK16-II/EAKIIH6 composite was tracked using the
NIR dye (=800 nm)-labeled goat anti-rabbit antibody (Rabbit-IgG800, 0.03 µM), which
binds to the rabbit derived H6-IgG. EAK16-II, EAKIIH6, αH6-IgG, and Rabbit-IgG800
were mixed and injected subcutaneously at the posterior flank or footpads of BALB/c
mice. Signal at the posterior flank was recorded real time using a Li-Cor Pearl Impulse
Imager for up to 11 days. Fluorescence intensity in the footpad was imaged using a LiCor Odyssey Imager ex vivo at 30 min, 6, 24, 48, and 72 h. Stability of IgG display
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system in tumors was tracked using the NIR dye (=800 nm)-labeled goat anti-chicken
antibody (Chicken-IgG800, 0.03 µM). The system was injected into 4T1 tumor on
BALB/C mice or B16 tumor on C57BL/6 mice. Signal in 4T1 tumor was monitored real
time on Pearl Impulse imager over 4 days. Fluorescence intensity in B16 tumor in the
footpad or tumor section (5 m thickness) was imaged on Odyssey ex vivo 24 h or 5 min
after injection respectively.
αRabbit-IgG800 was used to study the assembling and kinetic stability of EAK16II/EAKIIH6/αH6-IgG. The αH6-IgG is rabbit derived and it is not fluorescently labeled
(no near infrared dye labeled format is available commercially). Therefore, a secondary
IgG is used to detect binding of the primary antibody. αRabbit-IgG800, which is derived
from goat (against rabbit), can bind to the rabbit derived αH6-IgG. αChicken-IgG800 was
used as a model therapeutic IgG to demonstrate the assembling and stability of the full
system in tumor. αChicken-IgG800, which is derived from goat (against chicken), does not
bind to the rabbit derived αH6-IgG. Consequently, it can only be displayed onto the
membrane by interacting with pAG with its Fc domain.

Statistical analysis
Statistical analysis was performed in GraphPad Prism 5.0. Data were analyzed using one
way ANOVA and the Tukey-Kramer multiple comparison (α=0.05) or one-tailed
Student’s t-test (α=0.05) as indicated. Data shown represent mean and standard deviation.
n indicates number of replicates/animals in each group.
57

Results
The co-assembly of EAK16-II and EAKIIH6 was designed to display model therapeutic
antibodies via intermediate proteins (Figure 3-1). Anti-His-tag antibodies (H6-IgG)
cross-link His-tags in the EAK16-II/EAKIIH6 membrane and, at the same time, provide
Fc for recognition by pAG. The hexavalent pAG allows a second (i.e. therapeutic)
antibody to be displayed via Fc, thereby orienting the Fab domains away from the
membrane surface. To confirm this design, the amphiphilic peptides (EAK16-II and
EAKIIH6) and intermediate proteins (H6-IgG and pAG) were characterized with or
without an IgG (clone 1D11, (122)) that binds to transforming-growth factors (TGF- as
a model therapeutic antibody. Staining with Congo red revealed the classical orange fibrils in EAK16-II (Figure 3-2a) and EAK16-II/EAKIIH6 (Figure 3-2b) membranes. As
previously reported by Zheng et al (50), these membranes were not seen in buffers
containing EAKIIH6 without EAK16-II (Figure 3-2c). Successive additions of H6-IgG
(Figure 3-2d), pAG (Figure 3-2e), and αTGF-β IgG (Figure 3-2f) resulted in retracted and
denser morphologies. These morphological changes may suggest the two antigen binding
domains of H6-IgG could effectively crosslink EAK16-II/EAKIIH6 fibrils when they
bind to His-tags on two different fibrils.

Since optical microscopy has limited

magnification, it was used to demonstrate that macroscopic and Congo red stainable
membranes had formed. Details of the antibody display system were further investigated
under SEM.

58

Figure 3-2 Optical micrographs of samples. Samples contain (a) EAK16-II, (b)
EAK16-II/EAKIIH6, (c) EAKIIH6, (d) EAK16-II/EAKIIH6 + H6-IgG, (e) EAK16II/EAKIIH6/H6-IgG/pAG, and (f) EAK16-II/EAKIIH6/H6-IgG/pAG/αTGF-β 1 IgG.
Images (40X; scale bar-50 µm) were captured using a cooled CCD camera immediately
after solutions (5 L) containing the respective peptides and/or proteins were spotted
onto glass slides into an equal volume of PBS (Congo red 0.01%). Figure adapted from
reference (123) with permission. Copyright (2013) American Chemical Society.
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SDS-PAGE
In SDS-PAGE, proteins are separated based on their molecular weights with smaller
proteins migrated farther in a polyacrylamide gel. SDS-PAGE was used to characterize
the non-covalent associations in the system by analyzing the fraction remained in solution
(Figure 3-3a). Greater than 90% of αTGF-β IgG (~160 kDa) were captured by the
membrane (Figure 3-3b, lane II). Without EAKIIH6, less than 25% of αTGF-β IgG
loaded were associated with the insoluble membrane (Figure 3-3b, lane III). Without
H6-IgG (~110 kDa), 31% of αTGF-β IgG were found in the soluble fraction (Figure 33b, lane IV), possibly due to non-specific entrapment of complexes formed between
αTGF-β antibodies and pAG (~60 kDa, not visible in image). Larger complexes of
αTGF-β antibodies and pAG are more susceptible to be trapped within the EAK16II/EAKIIH6 fibrous network. Without pAG, capture of αTGF-β IgG was low (< 25%)
(Figure 3-3b, lane V). The band near the 3.4 kDa mark is attributed to excess EAKIIH6
that is excluded from assembly, which indicates that prototype formulation used requires
further optimization in the future.

The amount of EAK16-II needed to completely

incorporate certain amount of EAKIIH6 was further studied in chapter 5. These results
indicate that the intermediate proteins H6-IgG and pAG mediated the capture of αTGFβ IgG by the co-assembly.
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Figure 3-3 Analysis of interactions in the membrane system using SDS-PAGE
electrophoresis. (a) Unincorporated fraction from membranes settled under gravity in
500 µl PBS incubated at 37C overnight. (b) Lane I: αTGF-β IgG; lane II, EAK16II/EAKIIH6/H6-IgG/pAG/αTGF-β IgG; lane III, EAK16-II/H6-IgG/pAG/αTGF-β
IgG (system without EAKIIH6); lane IV, EAK16-II/EAKIIH6/pAG/αTGF-β IgG (system
without H6-IgG); lane V, EAK16-II/EAKIIH6/H6-IgG/αTGF-β (system without
pAG). (c) Band intensities were quantified using ImageJ. Percent loading was
determined based on the amount of αTGF-β IgG added to the system (lane I). Figure
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adapted from reference (123) with permission. Copyright (2013) American Chemical
Society.
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Scanning electron microscopy
Having established that a model therapeutic IgG could be displayed on the membrane via
His-tags, SEM was used to examine the structures in detail (Figure 3-4). Micrographs
with successive additions of each component were compared. Consistent with those
reported by other groups (58, 124), the mean width of the fibrils in the EAK16-II network
(Figure 3-4a) was determined to be 9.3 nm (2.1). The EAK16-II/EAKIIH6 co-assembly
was found to have a similar morphology seen in pure EAK16-II but with thicker fibrils
(mean width = 15.9 nm2.6) (Figure 3-4b), which may result from appending His-tags.
Successive additions of H6-IgG (Figure 3-4c), pAG (Figure 3-4d) and αTGF-β IgG
(Figure 3-4e) coincided with the appearance of particulates clustering at an average of
17.4 nm (7.3) apart when all components were added. The particulates were found to
have a mean diameter of 16.6 nm (±10.6), a dimension consistent with the length of two
extended Fab domains (16.9 nm) as suggested by Ma et al (33). Since distances among
adjacent particles both on the same fibril and different fibrils were measured, particles
closer than domains (16.9 nm) may locate on two different fibrils. The size range (Figure
3-4f) suggests individual (non-aggregating) αTGF-β IgG molecules were the most
frequent species. The smaller particulates (5-16 nm) might represent individual pAG on
the fibrils. Larger particulates (16-38 nm) might be attributed to IgG/pAG imaged from
multiple perspectives (relative to the vertical axis of the complex) due to convolutions in
the entangled fibrils. The few particulates greater than 38 nm might represent each pAG
bound with two or more IgG molecules (Figure 3-4g). These micrographs confirmed that
IgG molecules were spatially clustered on the membrane.
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Figure 3-4 SEM images of samples. SEM images (5000X magnification) of samples
with (a) EAK16-II, (b) EAK16-II/EAKIIH6, (c) EAK16-II/EAKIIH6 cross-linked with
H6-IgG, (d) EAK16-II/EAKIIH6/H6-IgG/pAG, and (e) EAK16-II/EAKIIH6/H6IgG/pAG/αTGF-β IgG. Samples were fixed and lyophilized prior to evaluation. (f) Size
distribution of the particles in image e was evaluated using an interactive measurement
program in Axiovision 4.6.3. (g) Proposed configurations of IgG complexes on fibrils.
Figure adapted from reference (123) with permission. Copyright (2013) American
Chemical Society.
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Antigen binding activity of immobilized antibodies
To demonstrate that the immobilized antibodies remained active, αTGF-β IgG loaded
membranes were tested in vitro using ELISA (Figure 3-5). Membranes established with
αTGF-β or an irrelevant IgG were placed on a mesh filter (pore size =8 m) onto which
media containing TGF-were placed. The assumption is that displayed antibodies would
be able to recognize and bind to targeted antigens because their native conformations and
activities would not be disrupted by the tethering mechanisms.

Therefore, a lower

concentration of TGF- shall be expected in the filtrate. Concentrations of TGF- in the
filtrate (unbound) were measured using ELISA. The system removed 57% to 61% of
TGF-β from the B16 and 4T1 media, respectively (Figure 3-5b). This was calculated by
comparing the concentrations of cytokine in the flow-through with (“αTGF-β IgG”) and
without (“Inert membrane only”) the system. Loading an irrelevant antibody (“Irrelevant
IgG”) onto the membrane resulted in no depletion. The membrane depleted 94 pg (3.8
fmol) of TGF- per microgram (6.7 pmol) of αTGF-β IgG in the system (Figure 3-5b).
Similar results were observed when the components were admixed into TGF-β containing
media. Using this second method, it was determined the system removed 71% to 82% of
TGF-β from the B16 and 4T1 media, respectively (Figure 3-5c). 141 pg (5.6 fmol) of
TGF- were depleted per microgram (6.7 pmol) of αTGF-β IgG (Figure 3-5c). This
relatively low efficiency was not unexpected. The cytokine concentrations are below the
saturation point at which all theoretical available antigen-binding sites would be occupied.
The loading capacity of antibodies and available antigen binding sites warrants further
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studies. These data show that IgG molecules localized on the membrane remained in its
native conformation and were able to bind to its cognate antigen.
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Figure 3-5 Antigen binding function of immobilized αTGF-β IgG. (a) Selfassembling components, including αTGF-β IgG, were formed on mesh filter or in PBS
and analyzed for antigen neutralizing capacity. Concentrations of TGF-β in the filtrate (b)
or supernatant (c) were determined using ELISA. Statistical significance was confirmed
by one way ANOVA and Tukey’s multiple comparisons (n=3, ***p<0.0001, **p<0.01).
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Concentrations of TGF- in media were below saturation and not all αTGF-β IgG
antigen-binding sites were expected to be occupied. Figure adapted from reference (123)
with permission. Copyright (2013) American Chemical Society.
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In vivo assembly and stability of EAK16-II/EAKIIH6 membrane co-assembly
The in vitro evidence shows that the EAK16-II/EAKIIH6 membrane provided a physical
mechanism by which IgG molecules can be co-localized. To demonstrate that the His-tag
surface could self-assemble in vivo, the peptides were injected (in deionized water)
subcutaneously into the posterior flank of BALB/c mice. In addition to the amphiphiles,
H6-IgG were co-administered to cross-link the His-tags in situ. Assembly of the three
components, namely, EAK16-II, EAKIIH6 and H6-IgG, was monitored using a NIR
dye (=800 nm)-labeled goat anti-rabbit antibody (Rabbit-IgG800). This dye-labeled
antibody binds to H6-IgG.

Figure 3-6a shows that the composite (“His-tagged

membrane”) remained at the injection site for up to 264 h, as evidenced by the
concentrated fluorescence at the site of injection. Without EAKIIH6, the fluorescent
intensity (FI) at the injection site was significantly less; at 24 h, mice received EAK16II/EAKIIH6/H6-IgG registered a FI of 646 (arbitrary unit), compared to 118 in mice
that received EAK16-II/H6-IgG. Mice received only Rabbit-IgG800 showed relatively
low local fluorescence (61) at 24 h and fell near background thereafter (Figure 3-6b).
These results show that the co-assembly of EAK16-II/EAKIIH6 displayed His-tags in
living mice.
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Figure 3-6 Stability of EAK16-II/EAKIIH6 (molar ratio 4:1) co-assembly in BALB/c
mouse subcutaneous flank. Solutions containing EAK16-II, EAKIIH6, H6-IgG, and
Rabbit-IgG800 (“His-tagged membrane”) were injected into mice (n=2) using insulin
syringes. “Membrane” refers to animals received EAK16-II, H6-IgG, and RabbitIgG800. “Rabbit-IgG800” indicates animals injected with only the fluorescent antibody.
(a) Representative real time images of fluorescent signal in the same mouse. All images
were exported with same setting from Licor Pearl Impulse. (b) Kinetic profiles of
fluorescent intensity decay. Fluorescent quantifications obtained from mice received
membranes without H6 and those received free Rabbit-IgG800 were modeled as a
monophasic decay using GraphPad Prism. (c) Schematic of the mode of His-tag
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detection. Figure adapted from reference (123) with permission. Copyright (2013)
American Chemical Society.

72

Mice injected with EAKIIH6 and H6-IgG showed near background fluorescence
after 24 h (Figure 3-7). This result confirmed in vivo that without EAK16-II, EAKIIH6
cannot assemble into insoluble membrane in subcutaneous space in mice. Consequently,
without EAK16-II, EAKIIH6 could not slow down the clearance of IgG in tumors. This
is consistent with data previously shown. The micrograph Figure 3-2c in the current
chapter indicates the lack of macroscopic membranes when EAKIIH6 was spotted in
buffers on glass slides. Additional supporting evidence has been described in Zheng’s
dissertation work (50, 52). Without EAK16-II, EAKIIH6 adopts mostly -helical and not
-strand conformation required for self-assembly; EAKIIH6 per se does not coprecipitate nickel-bound horseradish peroxidase from aqueous buffers.

Figure 3-7 Representative time-lapse images showing the lack of gelation with
EAKIIH6 in vivo. Plotted data show fluorescent decay of Rabbit-IgG800 co-injected
with H6-IgG and EAKIIH6 in a BALB/c mouse (n=1). The amount of EAKIIH6
(187.5 g) injected was equivalent to the total peptide weight in the EAK16-II/EAKIIH6
(molar 4:1) mixture. All images were exported with the same settings from Licor Pearl
Impulse. Figure adapted from reference (123) with permission. Copyright (2013)
American Chemical Society.
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Comparing the rates of FI decline revealed that cross-linking of the His-tags was
critical in maintaining antibodies locally (Figure 3-6b). From 30 min to 24 h, the rate of
decline in mice that received EAK16-II/EAKIIH6/H6-IgG was determined to be 0.48%
of the initial fluorescence (InitF; 30 min after injection) per hour, which is an order of
magnitude slower than those in mice that received EAK16-II/H6-IgG (3.2%InitF.h-1).
Free Rabbit-IgG800 also declined rapidly at 4.0%InitF.h-1. Thereafter, the His-tag crosslinked membrane remained relatively stable; from 24 h to 264 h, FI in mice that received
EAK16-II/EAKIIH6/H6-IgG declined at a relatively slow rate of 0.19%InitF.h-1 (Figure
3-6b).

The decline of free Rabbit-IgG800 followed first-order kinetics (R2=0.98, Ke =

0.12 h-1), as in the case when the same fluorescent antibody was co-administered with
EAK16-II and H6-IgG (R2=0.94, ke = 0.06 h-1). Clearance of Rabbit-IgG800 in mice
injected with His-tagged membrane indicated multi-compartmental kinetics, but it was
clear that the AUC (1.4×105 FI.h) was 10-fold and 11-fold higher than the membrane
without His-tags (1.3×104 FI.h) and free fluorescent IgG (1.2×104 FI.h), respectively.
Similar observations were made in mouse footpads. Injection of Rabbit-IgG800 alone
resulted in near complete loss of fluorescence within the first 24 h (Figure 3-8a). When
injected with EAK16-II, EAKIIH6 and H6-IgG, Rabbit-IgG800 remained at injection
site longer compared to when the same antibody was injected with only EAK16-II and
H6-IgG. Local FI was found to be 57.5 (8.0) and 15.4 (1.6) (p= 0.0061), respectively,
48 h after injection. From 30 min to 24 h, the rate of FI decline in mice that received
EAK16-II/EAKIIH6/H6-IgG was determined to be 2.3%InitF.h-1, which was slower
than those in mice that received EAK16-II/H6-IgG (3.4%InitF.h-1) and Rabbit-IgG800
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(4.0%InitF.h-1).

Between 24 h to 72 h, FI in mice that received EAK16-

II/EAKIIH6/H6-IgG declined at a relatively slow rate of 1.1%InitF.h-1.

Marginal

fluorescence was seen in mice that received EAK16-II/H6-IgG in the same period
(Figure 3-8b). These observations in two anatomical sites (flank and footpad) established
that the self-assembling process could take place in vivo and that His-tag cross-linked
EAK16-II/EAKIIH6 remained locally for an extended duration.
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Figure 3-8 Stability of EAK16-II/EAKIIH6 in BALB/c mouse footpads. (a)
Representative ex vivo images of footpads injected with solutions containing EAK16-II,
EAKIIH6, H6-IgG, and Rabbit-IgG800 (“His-tagged membrane”) using insulin
syringes. “Membrane” refers to animals received EAK16-II, H6-IgG, and RabbitIgG800. “Rabbit-IgG800” indicates animals injected with only the fluorescent antibody.
All images were exported with the same settings from Licor Odyssey. (b) Fluorescent
intensities was analyzed by one way ANOVA and Tukey’s multiple comparisons (n=3;
***p<0.0001, **p<0.01, *p<0.05). Figure adapted from reference (123) with
permission. Copyright (2013) American Chemical Society.

77

Stability of IgG displaying system in tumors
Having demonstrated the stability of the His-tag membrane in vivo, we next investigated
the ability of intermediate proteins to retain IgG with the membrane in tumors. This was
examined using two mouse tumor cell lines.

The mammary line 4T1 arose from a

spontaneous malignant lesion in a BALB/c mouse (125) and the B16-F10 line was
derived from a melanoma in a C57BL/6 mouse (126). While both B16-F10 and 4T1 are
of epithelial origins, they differ in their physical properties. The extracellular matrix of
4T1 tumors is relatively dense, while B16-F10 tumors tend to contain more fluid.
McGuire et al reported that the collagen content in 4T1 tumors is approximately six times
of that in B16-F10 tumors (124).
compared to B16-F10 tumors.

Consequently, 4T1 tumors are less deformable

The difference might affect the efficiency of the

assembling process and retention. Tumors are palpable about 10 days after inoculation
and ready for experiments when they reach about 0.5 cm × 0.5 cm, at which angiogenesis
and inflammation are adequately developed (127-129).

However, the anatomical

difference also dictated the stage at which the tumors were used in the experiments.
Limited space is available for B16 tumors to grow in the mouse footpad, while 4T1
tumors established in the posterior flank can expand considerably. Hence, B16 and 4T1
tumors were studied at sizes of 0.2 cm × 0.2 cm and 0.5 cm × 0.5 cm respectively.
Retention of antibodies in 4T1 tumors was monitored in live mice using the Li-Cor
Pearl Imager. Chicken-IgG800 injected without the assembling components retained
poorly in 4T1 tumors (Figure 3-9a); after 24 h, local FI decreased from 249 to near
background level at a rate of 10% InitF.h-1. Likewise, Chicken-IgG800 injected with
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only pAG did not accumulate beyond 24 h.

Conversely, Chicken-IgG800 co-

administered with the assembling components remained in tumors for at least 120 h.
Between 24 to 120 h, retention of the fluorescent antibody appeared steady, as evidenced
by the slow rate of fluorescence decline during the period (Figure 3-9b).
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Figure 3-9 Live animal imaging of membrane-immobilized IgG in 4T1 tumors.
Solution mixture of EAK16-II, EAKIIH6, H6-IgG, pAG, and Chicken-IgG800
(“System”) were injected into medium size 4T1 tumors established on the posterior flank
of BALB/c mice. Controls include injecting all components without pAG (“no pAG”) or
without the amphiphilic peptides (“Chicken-IgG800 + pAG”). Fluorescent antibodies
(“Chicken-IgG800”) in saline were also included as a control. (a) Representative images
of fluorescence over time in the same mice in each group. All images were exported with
the same settings from Licor Pearl Impulse. (b) Fluorescent intensity in tumors injected
with all components (“System”) or Chicken-IgG800 over time (n=2). The time of
injection was based on the tumor reaching the half-maximal allowable size. Figure
adapted from reference (123) with permission. Copyright (2013) American Chemical
Society.
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Similar results were observed in B16-F10 tumors established in the footpads of
C57BL/6 mice (Figure 3-10a). Free Chicken-IgG800 was not detectable after 24 h, but
fluorescence from the antibody administered with the clustering components remained
locally at least 4-fold higher (Figure 3-10b). Taken together, these data indicate that the
clustering system can partially overcome the IgG clearance mechanisms in the tumor
microenvironment.

To determine the extent of antibody distribution, tumors were

excised 5 minutes after injection and sectioned (5 m). Figure 3-10c shows sections of a
B16 tumor (implanted on the flank) representing the edge of the lesion towards the center
and out to the opposite edge. All sections show strong fluorescence. It could therefore
postulate that the pressure exerted from the syringe injection drove the peptides and
proteins through the interstitial gaps in the lesion. The convective flow takes place
simultaneously with the self-assembling process.

As the self-assembly completes,

antibodies are stably displayed to resist the IgG clearance in tumors.
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Figure 3-10 Ex vivo imaging of membrane-immobilized IgG in B16-F10 tumors.
The time of injection was based on the size of the tumor reaching the half-way point
limited by the anatomy. Solution mixtures of EAK16-II, EAKIIH6, H6-IgG, pAG, and
Chicken-IgG800 (“System”) were injected into of C57BL/6 mouse footpads with visible
and palpable tumors.
Fluorescent antibodies (“Chicken-IgG800”) in saline were
included as the control. (a) Fluorescence in B16 melanoma 24 h after injection of dyelabeled IgG. All images were exported with the same settings from Licor Odyssey. (b)
Statistical significance was confirmed by Student’s t test (n=3; **p <0.01). (c) Optical
outline (top panel) followed by fluorescence images of tissue sections (5 m) of a B16
tumor (established on the flank of a C57BL/6 mouse) injected with all components
(“System”) showing permeation of dye-labeled IgG throughout the lesion. Figure
adapted from reference (123) with permission. Copyright (2013) American Chemical
Society.
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Discussion
We describe herein an injectable system by which IgG molecules can be retained in vivo
through directional binding.

Immobilization of antibody molecules onto a common

surface could be accomplished by adsorption through electrostatic interactions or
hydrophobic means (130, 131). Such random associations often result in altered protein
conformations, leading to denaturation and loss of functions.

Direct coupling of

antibodies to a chemically activated surface might generate overly crowded proteins,
resulting in diminished function due to steric hindrance (131). Fc-binding proteins such
as pAG have been used as intermediates to orient Fab away from the adsorptive surface
(132). The strong affinities of proteins A and G (equilibrium constants ranging from 1.13
x108 to 2.90 x107 M-1) (133) for Fc ensure stable association and proper orientation.
While the strategy of employing intermediate proteins to immobilize antibodies has been
explored in vitro, few studies have demonstrated the extent to which such assembling
could take place in vivo.
In the present chapter, we show that co-assembly of EAK16-II and EAKIIH6 can be
established in vivo by injection using standard syringes (28’ gauge). The co-assembly
displayed His-tags for up to 11 days. It should be noted that mice administered with the
peptide amphiphiles behaved normally and exhibited no gross systemic toxicities (food
intake and body weight) for the duration of the experiment. The immobilizing system
could be used to partially overcome the antibody clearance mechanisms in tumors, as
evidenced by the prolonged retention of IgG in the 4T1 and B16-F10 lesions. In both
models, immobilized IgG remained in tumors significantly longer than free IgG. As
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suggested in studies reported by others (134, 135), infusions provided the convective
force to drive the self-assembling components through the tumor interstitium, dragging
the fluorescent IgG along into the tumor mass. Because the Fc domains of membranebound IgG were occupied by pAG, clearance by phagocytes via Fc receptors was
inhibited.

The eventual clearance of the IgG from tumors likely resulted from gradual

loss of H6-IgG and/or pAG non-covalently associated with the fibrils. It might also
result from dissociation of EAKIIH6 from the EAK16-II/EAKIIH6 co-assembly in the
tumor microenvironment.
The SEM images showed particulates clustered on fibrils. These particulates were
within a size range consistent with predicted molecular dimensions of IgG (Figure 3-4g),
which implied that antibodies were displayed on the membrane. Smaller but sparse
particulates could be seen in membranes added with only H6-IgG (Fig. 3-4c). Mixing
two different peptide amphiphiles yielded fibrils with increased width possibly due to
appending His-tags. The length of two extended Fab domains in an IgG molecule has
been estimated about 16.9 nm. Each IgG should be at least 17 nm apart along the fibril
length to avoid steric interference. On the other hand, optimizing the density of bioactive
IgG would have to consider the nature of the target. For soluble proteins, the dimensions
(in which diameters typically range in the tens of nanometers) of the monomers or
oligomers would dictate the optimum. For the much larger ( > 10 m) cellular targets,
concentration of membrane-bound antigens would likely override the spatial arrangement
of antibodies on the membrane.
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SDS-PAGE demonstrated that the association between a model IgG and the EAK16II/EAKIIH6 co-assembly was specifically mediated by the intermediate proteins.
Loading of the model therapeutic IgG (anti-TGF-) was highly efficient, and was a
function of pAG, H6-IgG and His-tags. Non-specific interactions might be attributed to
adsorption of proteins within cavities in the crossed fibrils. High molecular weight
complexes of IgG/pAG might be entrapped within the membrane. IgG displayed on
EAK16-II/EAKIIH6 was demonstrated to bind to its cognate antigen. Because the design
does not involve chemical coupling, antibody molecules are less likely to denature. The
in vitro characterization suggests robust coacervation of the components.

Conclusions
The current chapter provides both in vitro and in vivo proof-of-concept evidences that
antibodies are displayed onto EAK16-II/EAKIIH6 membrane through intermediate
proteins (αH6-IgG and pAG). In SDS-PAGE, more than 90% of model IgG added were
associated with the membrane. Without any of the components (EAKIIH6, αH6-IgG, or
pAG), a higher fraction of antibodies remained in the solution. The small fraction of
antibodies removed from solution were possibly entrapped within cross-linked fibrils
non-specifically. SEM data indicate antibodies were successfully displayed onto the
membrane. The sizes of clustered particulates on fibrils corresponded well with the
distance of two Fab domains, which suggests most His-tags displayed one IgG in current
formulation. One major concern with our antibody display system is the antigen binding
activity of displayed antibodies. Using TGF-β as the model antigens, displayed anti87

TGF-β IgG remained biologically active and were able to remove TGF-β from three
source media. The assembly and stability was demonstrated in vivo. EAK16-II and
EAKIIH6 can self-assemble in vivo to provide accessible His-tags stably for up to 11
days. Using the described antibody display system (EAK16-II, EAKIIH6, αH6-IgG and
pAG), antibodies are retained effectively in tumor after intratumoral injection.
Nonetheless, SDS-PAGE data shows there was excessive EAKIIH6 in the formulation
used (molar ratio of EAK16-II: EAKIIH6 = 4:1, Figure 3-3).

After intratumoral

injection, a majority of antibodies injected were cleared from the site of injection in 24 h
(Figure 3-9). Hence, stepwise optimization is required for maximal performance in vivo.
The antibody loading capacity and available antigen binding sites warrants close
examinations. This may be investigated by escalating the amount of antigen added until
saturation is reached. The magnification of SEM images was not high enough to reveal
the orientation and number of antibodies displayed.

Cryo-transmission electron

microscopy (Cryo-TEM) might provide further details of the antibody display system
(136, 137).

In addition, the in vivo therapeutic advantages remain to be demonstrated.

The ability to reduce IgG clearance in tumors opens opportunities for using therapeutic
antibodies to modulate cancer-associated T cells. These include anti-CTLA-4 IgG that
amplifies T cell responses toward cancers. Intravenous infusion of these agents has been
associated with immune related toxicities due to non-specific effects on bystander
leukocytes (138). An effective local depot could mitigate these complications.
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CHAPTER 4
Antibody Functionalized Peptidic Membranes Impede Trafficking of
Allogeneic Skin Antigen Presenting Cells
Abstract
The performance of the in situ antibody display system to attenuate allograft rejection
was tested in a skin transplant mouse model. Self-gelling anti-donor antigen presenting
cells (dAPCs) membrane was shown to attenuate T cell activity in recipient mice to donor
graft with fully mismatched major histocompatibility complexes (MHC). Functionalized
peptidic membranes were used to impede trafficking of dAPCs to draining lymph nodes
in recipient mice. Membranes loaded with antibodies were found to remain underneath
normal and grafted skins for up to 6 days. dAPCs were targeted by using an antibody
that binds to a class II MHC molecule (I-Ad) expressed exclusively by donor cells. In
treated mice, fewer dAPCs were found in graft-draining lymph nodes. Recipient T cells
from these mice produced lower concentrations of interferon-gamma (IFN-) cultured ex
vivo with donor cells. Taken together, the data suggest that the strategy has the potential
to alter the natural course of transplant rejection. The platform can be fit with different
antibodies to mitigate multiple rejection mechanisms simultaneously.

Introduction
In this chapter, performance of the in situ forming fibrillar EAK16-II/EAKIIH6
membrane to attenuate immune rejection of allogeneic skins is described. Human skin
89

allograft is the “gold standard” biological dressing for temporary wound closure (139).
Patients with partial and full-thickness burns benefit from intact epidermis and dermis;
together these serve as a protective barrier to minimize desiccation of the underlying
exposed tissues, limit water evaporation, reduce bacterial contamination, relieve pain, and
promote wound healing by accelerating re-epithelialization (139).

However, the

heightened antigenicity of skin allografts drives powerful allospecific T cell responses in
recipients (7).
Calcineurin inhibitors (cyclosporine A and tacrolimus) and mAb targeting IL-2
receptors are the mainstays in managing allograft rejection (140-142). These agents exert
their immunosuppressive effects by dampening the activation, proliferation and survival
of all T cells through down-regulation of interleukin-2. Patients exposed to these drugs
have increased risk of developing opportunistic infections (143) because of the nonselective immunosuppression as well as the fact that skin flora may contain antibioticresistant Staphylococcus aureus (144, 145). Herein we propose to generate selective
immuosuppression by exploiting a fundamental molecular difference between donor and
recipient cells: class II MHC (MHC-II) molecules expressed by donor antigen-presenting
cells (dAPCs).
Acute rejections are driven by mismatched class I and II MHC molecules expressed by
donors and recipients whereby the latter mount potent T cell responses against skin
allografts (54). Allograft survival correlates with density of resident dAPCs. Within
hours following allogeneic skin transplantation, dAPCs residing within allografts begin
migrating to host lymph nodes (146-148). Once there, dAPCs activate allospecific T
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cells via MHC and costimulatory molecules (7, 54). Inside lymph nodes recipient CD4
helper T cells recognizing mismatched MHC-II molecules are activated to drive CD8 T
cell differentiation into cytotoxic T cells (CTLs) (Figure 4-1). Presentation of MHC-II
antigens is critical because generation of CTLs is compromised without CD4 T cell
participation. With visceral allografts, activation of CD4 and CD8 T cells are correlated
with frequency of dAPCs in lymph nodes (149-151).

Skin dAPCs include donor

Langerhans’ cells (dLCs) in the epidermis and dermal dendritic cells (dDCs). dLCs and
dDCs migrate in waves, with the trafficking complete within 4-5 days in rodent models
(152). Activated allospecific CD8 CTLs in turn migrate to the transplant site and damage
graft parenchyma via recognition of MHC class I molecules (54).

The magnitude of

rejection depends on the qualitative and quantitative encounter between dAPCs and
recipient T cells shortly after grafting (152).
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Figure 4-1 Schematic depiction of acute rejection of allograft. Shortly after the
transplantation, dAPCs in the allograft are activated (1) and migrate towards draining
lymph nodes (2). Host T cells in the draining lymph nodes are activated via direct
allorecognition by dAPCs (3). Activated T cells migrate to the allograft and mediate graft
rejection (4).
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Because acute rejection is a function of dAPCs accumulating in recipient lymph nodes,
methods have been devised to deplete dAPCs prior to transplantation.

Pre-clinical

strategies tested so far have been non-specific in nature; typically the methods require
systemic infusion of anti-leukocyte antibodies into donor animals before organ harvest
(153-155). While such preemptive strategies can be effective in delaying rejection of
allografts in animal models, translation to humans is complicated by the ethical concerns
and practicalities involved. Recognizing the unmet need, we envisioned a new strategy
by which dAPCs trafficking can be impeded selectively after transplantation.
Previously, we have discussed an injectable platform by which retention of IgG
molecules in local tissues can be enhanced (chapter 3). EAK16-II and related peptide
amphiphiles are utilized in particular for their environmental responsiveness (156).
These peptides undergo sol-gel phase transition at increasing ionic strengths; in deionized
water, these peptides can be injected as solutions into physiological environment to
establish gels in situ. The injectable system localizes IgG molecules in vivo through
directional binding (50, 123). Membranes loaded with antibodies can be established in
vivo by subcutaneous injection using hypodermic needled syringes. Such immobilization
partially overcomes antibody clearance mechanisms in tumors, as evidenced by the
prolonged retention of IgG in mouse mammary and melanoma lesions (123). In both
tumor types, localized IgG remained in tumors significantly longer than free IgG.
In the present chapter, the in vivo performance of the system of materials to localize
anti-MHC-II antibodies specific to dAPCs is demonstrated. The rationale is that mixtures
consisting of EAK16-II, its histidinylated analogue EAKIIH6, and intermediate proteins
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(αH6-IgG and pAG) would localize the antibodies at the graft-host interface. dAPCs
migrating toward draining lymph nodes would interact with the antibody functionalized
membranes, resulting in delayed and/or diminished encounter with T cells (Figure 4-2).
The strategy was examined in the current study using an allogeneic mouse skin graft
model. All MHC alleles between the donor and recipient are mismatched, rendering this
a stringent mode. Consequently, we did not expect to observe delay in rejection by using
the strategy alone. The purpose of the work was to characterize the αI-Ad membrane in
vitro and in vivo to assess feasibility of the concept instead of achieving full protection of
the allograft. To this end, we first investigated retention of a fluorescent-dye labeled IgG
co-administered with the self-assembling components under normal and grafted skins.
The immune responses toward the graft were then determined by analyzing T cell
responses in recipient mice. The data indicate that the platform can potentially become
clinical tools that mitigate the magnitude of acute rejection of skin allografts.
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Figure 4-2 Attenuation of T cell activity using anti-dAPCs membrane. Antibodies
targeting surface MHC-II molecules of dAPCs are displayed on the membranes of selfassembling peptides EAK16-II and EAKIIH6 through intermediate proteins (αH6-IgG
and pAG). Migrating dAPCs will be immobilized on the membrane due to the synergistic
multivalent interactions between displayed anti-MHC antibodies and cell surface MHC-II.
Hence, activation of host T cells through direct allo-recognition will be delayed or
abolished.
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Materials and Methods
Materials
Peptides were custom synthesized by American Peptide Company (Sunnyvale, CA) at
greater than 95% purity with termini acetylated or amidated. Peptides were reconstituted
in sterile MilliQ water (18.2 M at 25C) at 5 mg/mL (3 mM, EAK16-II) or 7.5 mg/mL
(3 mM, EAKIIH6). Rabbit anti-His-tag polyclonal antibody (αH6-IgG, 0.2 mg/mL) was
obtained from AnaSpec, Inc (San Jose, CA). Recombinant protein A/G (pAG) was
obtained from Pierce Biotechnology (Rockford, IL) and reconstituted to 0.25 mg/mL in
sterile deionized water. Anti-mouse I-Ad (MHC-II) antibody (αI-Ad, 0.5 mg/mL; clone:
39-10-8) was purchased from Biolegend (San Diego, CA). Allophycocyanin conjugated
anti-mouse MHC-II I-Ad antibody (0.2 mg/mL) was obtained from eBioscience (San
Diego, CA). DyLightTM 800 conjugated goat anti-chicken IgG (IgG800) was obtained
from KPL (Gaithersburg, MD) and reconstituted to 1 mg/mL in sterile deionized water.
RPMI-1640 and fetal bovine serum (FBS) were obtained from HyClone (Logan, Utah).
ACK lysing buffer and penicillin/streptomycin solutions were purchased from Lonza
(Walkersville, MD).

Skin transplantation
Six–to-eight week old female (certified-virus-free) BALB/c and C57BL/6 mice were
purchased from Charles River Laboratories (Wilmington, MA) and housed in the
Duquesne University Animal Care Facility.

Animals were handled in accordance to
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protocols approved by the Duquesne University Institutional Animal Care & Use
Committee. The transplant procedure was modified from a protocol described by Garrod
et al (157) (Figure 4-3). Briefly, the recipient C57BL/6 mice were anesthetized using
isoflurane (induction: 5%; maintenance: 3%) and administrated with Bupernex at 0.1
mg/kg intraperitoneally. Ear skin explants (dorsal layer) were prepared from BALB/c
mice and transplanted onto graft beds (each ~0.5 cm2) prepared in the flank of C57BL/6
mice. After surgeries, C57BL/6 mice were bandaged and recovered under infrared lamp.
Their activities (food and water intake and mobility) were monitored regularly (157).

Figure 4-3 Procedures of mouse skin transplantation. Dorsal ear skin of donor
BALB/c mouse is grafted onto recipient C57BL/6 mouse. After recovery, the activities of
recipient mice are monitored. Typically, allograft is rejected in about 10 days.
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In vivo stability of IgG membrane in subcutaneous space and under the skin graft
Anti-chicken IgG labeled with a near infrared dye emitting at 800 nm (IgG800) was used
as a model antibody to investigate the assembling and stability of the system in vivo.
EAK16-II (100 µg in 20 µL) was mixed with 37.5 µg (in 5 µL) of EAKIIH6. In a second
vial, 2 µg αH6-IgG, 2 µg IgG800, and 0.375 µg pAG were mixed. The peptides and
antibodies solutions were withdrawn into the same insulin syringe (28 G’ needle) and
injected into the subcutaneous space in footpad or at flank of BALB/c mice.
Fluorescence in the footpad was imaged ex vivo at 30 min, 6, 24, 48, and 72 h. Footpads
were collected and stretched out on a 15x100 mm dish using scotch tape for ex vivo
imaging. Images were captured using an Odyssey Imager (Li-Cor, Inc, Lincoln, NE) and
measured at an intensity of 1.0 with focal distances of 3.2 mm and 3.5 mm.
Quantification of fluorescent intensity was performed by drawing a polygon outlining the
shape of the footpad. The averaged signal of three blank footpads at each focal distance
was subtracted as background. Data reported represent intensities averaged from the
measurement performed at each focal distance.
Signal at the posterior flank was recorded real time in vivo for up to 4 days.
Anesthetization was induced using isoflurane (induction 5%, maintenance 3 %) for real
time in vivo imaging. Abdominal hairs were removed prior to scanning. Mice were
scanned prior to injection and monitored at the indicated times after injection using a
Pearl Impulse imager (Li-Cor, Inc.). All images were collected using the same threshold
and resolution (170 µm) settings. Oval-shaped regions of interest were defined at the site
of injection using the contralateral flank as background. Fluorescence was quantified
98

using the Impulse (2.0) software (Li-Cor, Inc.) with a standard deviation multiplier of 10
and a search limit of 100 pixels.
To demonstrate the assembling and stability of the system under the skin graft, the
same amount of peptides and antibodies solutions were mixed and administrated onto the
graft bed of C57BL/6 mice before the skin was placed. Signal was monitored in realtime using a Li-Cor Pearl Impulse Imager for up to 6 days as in the previous experiment.

Detection of I-Ad+ dAPCs in draining lymph nodes
The capability of anti-I-Ad membrane to impede the trafficking of dAPCs to host draining
lymph nodes was studied using flow cytometry. αI-Ad IgG with or without the antibody
display system were administrated onto the graft bed prior to the skin graft. Draining
lymph nodes (inguinal, popliteal and axillary) were collected and pooled 1 day, 2 days, or
3 days after transplantation.

Single cell suspensions were prepared by mechanical

crushing and filtering through 70 µm nylon cell strainers.

APCs (both donor and

recipient) were enriched using BD IMag mouse dendritic cell enrichment set (BD
Bioscience, San Jose, CA). APCs were re-suspended in 200 µL 3% FBS PBS. Half of
the cell suspension (100 µL) was stained with 2 µL allophycocyanin conjugated antimouse MHC-II I-Ad antibody (4 µg/mL) by 1 h incubation at 4°C in the dark. Unbound
antibodies were washed away by centrifugation and resuspending in PBS three times.
The other half, which serves as the unstained control, was treated with the same
procedure but no staining antibody was added. Samples were analyzed using a BD
Accuri C6 flow cytometer (BD, Franklin Lakes, NJ) at 50,000 events per sample.
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Allogeneic APC-T cells reaction
To demonstrate that systemic T cell responses were attenuated, splenic T cells from
recipient C57BL/6 were cultured with naïve BALB/c APCs. Six days after
transplantation, the spleen was collected from BALB/c mice to prepare naïve APCs.
Single cell suspension was prepared by dish crushing, hypotonic solution (ACK lysing
buffer) treatment and filtering through a 70 µm nylon cell strainer. Cells were cultured in
1 mL complete RPMI medium with 5 ng/mL GM-CSF at a density of 1 million/mL
overnight. Culture medium was gently pipetted to remove non-adherent cells. Recipient
C57BL/6 mice were euthanized and single cell suspension was prepared from the spleen
at 0.5 million/mL. C57BL/6 splenic T cells (1 million in 2 mL medium) were added into
previously obtained naïve BALB/c APCs, and cultured for 48 h. Cell culture medium
was collected by centrifugation. ELISA was used to quantify the concentration of IFN-γ
(DuoSet mouse IFN-γ, R&D Systems, Minneapolis, MN) and IL-10 (DuoSet mouse IL10, R&D Systems) produced by recipient C57BL/6 T cells.

Statistical analysis
Statistical analysis was performed in GraphPad Prism 5.0. Data were analyzed using one
way ANOVA and Tukey-Kramer multiple comparison (α=0.05) or one-tailed Student’s ttest (α=0.05) as indicated.

Data shown represent mean and standard deviation.

indicates the number of animals in each group.
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Results
Mouse ear skin grafting is a robust method for measuring the magnitude of allograft
rejection (158). Excision of epidermal and dermal layers results in exposed underlying
tissues that mimic debrided burnt skins (159). The targets of the current strategy, dAPCs,
are interspersed within skin layers of mouse and human (54). LCs are immature DCs but
promptly mature upon encountering alloantigens while migrating to secondary lymphoid
tissues.

The density of these cells has been correlated with immunogenicity.

For

example, mouse tail skin, which contains few LCs, is significantly less antigenic than ear
skins (152).

We postulated that acute rejection can be attenuated by establishing

materials that capture dAPCs at the graft-host interface (Figure 4-2).

In vivo retention of IgG membranes in subcutaneous space
To determine the ability of the system to localize antibodies in subcutaneous space in
vivo, the fate of a NIR (=800nm) labeled IgG (hereafter “IgG800”) was tracked in
BALB/c mice (Figure 4-4 and 4-5). Superior stability was demonstrated by injecting the
materials into the footpads of BALB/c mice subcutaneously (Figure 4-4). Fluorescence
could be detected for at least 72 h when IgG800 was injected with the assembling
components, while IgG800 in saline (“Free IgG800”) was significantly lower at 6 h (p <
0.001) and marginal after 24 h (p < 0.001) compared to the former. Without pAG,
retention of IgG800 was significantly lower at 6 h (p < 0.01), 24 h (p < 0.001), 48 h (p <
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0.001) and 72 h (p < 0.001) compared to mice which received the antibody-membrane
treatment.

This indicated molecular interactions involving pAG (123).

However,

antibodies could still be non-specifically encapsulated into the fibrous structures of
EAK16-II/EAKIIH6 without pAG, which explains the fluorescence observed when pAG
was not added (system w/o pAG + IgG800).

Further evidence of localization was

supported by real-time optical measurements.

When injected into the mouse flank,

solutions containing IgG800 with self-assembling components showed remarkable
localization (Figure 4-5). Strong fluorescence was detected at the injection site for at
least 96 h, while low fluorescence was observed with IgG800 in saline after 24 h. Similar
to previous intratumoral studies (Figure 3-9), there was a significant loss of antibodies in
the first 24 h. Therefore, full optimization may be necessary for maximal performance in
the future. Nonetheless, these in vivo results show that the self-assembling formulation
was effective in retaining IgG locally.
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Figure 4-4 Stability of the antibody display system in BALB/c mouse footpads. (a)
Representative ex vivo images of footpads injected with solution containing EAK16-II,
EAKIIH6, αH6-IgG, pAG, and IgG800 (System + IgG800) or solution of EAK16-II,
EAKIIH6, αH6-IgG, and IgG800 (System w/o pAG + IgG800) or IgG800 alone in PBS (Free
IgG800). All images were exported with the same settings from Licor Odyssey. (b)
Fluorescent intensity in footpads quantified in Odyssey. Statistical significance
(compared to System + IgG800) was analyzed by one way ANOVA with Tukey’s multiple
comparison (0.5 h, 6 h, and 24 h) or student’s t test (48 h and 72 h) (n=5 for System +
IgG800 and System w/o pAG + IgG800, n=3 for Free IgG800, ***: p < 0.001, **: p < 0.01).
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Figure 4-5 Real time monitoring of antibody localization in vivo. (a) Representative
real time images of BALB/c mice injected with solution containing EAK16-II, EAKIIH6,
αH6-IgG, pAG, and IgG800 (System + IgG800) or IgG800 alone in PBS (Free IgG800) at the
lower flank. All images were exported with the same settings from Licor Pearl Impulse.
(b) Fluorescent intensity at the site of injection (n=2).
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In vivo stability of IgG membranes under skin grafts
Having established that the self-assembly process could take place in vivo in normal
subcutaneous space, the ability of the system to localize at the site of allograft
implantation was examined. Membrane components mixed with IgG800 were established
in the graft bed immediately prior to placement of allogeneic skins.

Fluorescence

underneath the graft was monitored in live mice for 6 days (Figure 4-6). IgG800 delivered
with the assembling components showed superior localization. As early as 5 minutes
after injection, local fluorescent intensity (FI) registered at least two-fold higher than in
mice received IgG800 without the components. FI in mice received the antibody in
membrane were significantly higher on day 3 (p < 0.01) and day 6 (p < 0.01) when
compared to those in mice that received IgG800 in saline. Bandages have to be removed
during NIR imaging; however, premature removal of bandages would affect survival of
grafts.

Therefore, mice were scanned only once on day 3 in addition to prior to

bandaging (5 min) and after removal of bandages (day 6). The system was able to retain
antibodies more effectively at the host-graft interface compared to tumors and normal
subcutaneous space. Less than 50% fluorescent drop was observed even on day 3. This
slower clearance might result from limited fluid convection and impaired lymphatic
drainage (160, 161). These results indicated that the assembling components provided a
mechanism by which IgG were retained at the graft-host interface.
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Figure 4-6 Real time stability of antibody display system at the graft site. (a)
Representative real time images of recipient C57BL/6 administrated with solution
containing EAK16-II, EAKIIH6, αH6-IgG, pAG, and IgG800 (System + IgG800) or IgG800
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alone in PBS (Free IgG800) at the graft bed prior to the skin graft. All images were
exported with the same settings from Licor Pearl Impulse. (b) Fluorescent intensity at the
graft site. Student’s t test was used for statistical analysis at each time point (n=4 for
System + IgG800 and n=3 for Free IgG800 due to one failed surgery, ***: p < 0.001, **: p
< 0.01).
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Evidence of impeded dAPCs trafficking to lymph nodes
To determine the extent to which dAPCs trafficking was impeded by membranes loaded
with anti-I-Ad IgG (hereafter I-Ad), draining lymph nodes (inguinal, axillary, and
popliteal) of recipient mice were analyzed for the presence of I-Ad+ cells (Figure 4-7a).
I-Ad IgG were placed on graft beds with or without the self-assembling components
prior to grafting of ear skins. At predetermined time points after transplantation, draining
lymph nodes were excised from the mice after euthanization. Lymph nodes from each
mouse were pooled and stained for I-Ad+ cells. Counting cells in draining lymph nodes
serve as an indirect way to demonstrate that I-Ad+ cells are immobilized on the I-Ad
membrane. Evidence of co-localization of I-Ad+ and I-Ad membrane would further
strengthen our conclusion. The practical reason for not pursuing it is that the I-Ad
membrane cannot be separated from the graft or the host tissue for histology studies.
Flow cytometric analyses indicated that on day 2 I-Ad membrane-treated C57BL/6 mice
had 2.0% (±0.18) of dAPCs in draining lymph nodes, significantly lower (p < 0.05) than
that of C57BL/6 mice received I-Ad delivered in saline (3.5%±0.52; Figure 4-7c). IAd membrane-treated C57BL/6 mice showed lower (but not significantly different)
frequency of I-Ad+ cells on day 3 (Figure 4-7d). The two groups showed comparable
frequency of I-Ad+ cells on day 1 (Figure 4-7b).
Statistical significance of dAPCs frequency in draining lymph nodes was observed
only on day 2. One potential reason for that is the lag time for complete assembly of αIAd membrane due to limited fluid and salts in graft beds. According to Larsen et al.,
there are 921 ± 204 epidermal Langerhans cells (LCs) per mm-2 in a skin graft on day 0
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after transplantation (152). The density dropped to 370 ± 128 per mm-2 on day 1, then to
293 ± 110 per mm-2 on day 3, and eventually to 128 ± 105 per mm-2 on day 7. Thus,
upon placement of skin graft, dAPCs immediately migrated out (within the first few
hours) may have escaped the αI-Ad membrane, which is not fully assembled. The effect
seen on the second day may result from impeded trafficking from a second wave of
emigrated dAPCs.

Taken together with the in vivo stability studies, these results

indicated that enhanced localization of the anti-MHC-II antibodies was able to impede
the trafficking of dAPCs.
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Figure 4-7 Detection of I-Ad dAPCs in draining lymph nodes by flow cytometry. αIAd IgG was administrated at the graft bed with the self-assembling components (αI-Ad
membrane) or PBS (αI-Ad IgG, local) prior to the skin graft. Single cell suspension was
prepared from draining lymph nodes of recipient C57BL/6 mice and dendritic cells were
enriched. Cells were stained with Allophycocyanin conjugated anti-mouse MHC-II I-Ad
antibody, and flow cytometry was used to probe the frequency of I-Ad dAPCs. (a)
Representative flow cytometry histogram of dAPCs frequency at day 2 (unstained sample
and stained samples from each group). Student’s t test was used to confirm the statistical
difference on day 1(b, n=4, ns: not significant), day 2 (c, n=4 for αI-Ad membrane and
n=3 for αI-Ad IgG, local, *: p < 0.05), and day 3 (d, n=3, ns: not significant).
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Suppression of T cell responses in recipient mice
We next hypothesized that reduced dAPCs trafficking would manifest in altered systemic
T cell responses toward the allograft. To test this, T cells of recipient mice were analyzed
ex vivo to evaluate immune reactivity toward donor antigens. Lymphocytes isolated from
spleens harvested from transplanted animals were stimulated in vitro by culturing with
fresh leukocytes from naïve donor mice (Figure 4-8a). After 48 h, culture supernatants
were analyzed using ELISA to determine the concentrations of IFN-, a characteristic
cytokine produced by activated T cells in cell-mediated rejection.
The results indicated that mice received I-Ad membrane yielded T cells that were
hypo-responsive.

Splenic T cells recovered from mice received I-Ad membrane

produced 4.4 ng/ml (±1.7) IFN-γ, in contrast to 15.1 ng/ml (±3.4) and 22.1 ng/ml (±5.1)
from mice received only I-Ad in saline (I-Ad IgG , local; p < 0.01) or the amphiphilic
peptides (EAK16-II/EAKIIH6; p < 0.001), respectively. T cells from transplanted mice
administered with the peptide amphiphiles without I-Ad produced high levels of IFN-.
Low levels of IFN- were released from T cells from mice transplanted with isografts
(C57BL/6 ear  C57BL/6 hosts) in which no rejection was expected (Figure 4-8b).
Generally low levels of IL-10 were detected in all groups with T cells from the mice (<
200 pg/ml). Co-cultures from mice treated with the system were found to have less IL-10
than the rest (Figure 4-8c). Collectively, the differential cytokines produced by recipient
T cells support the notion that T cell responses were attenuated specifically with local
depositions of I-Ad membranes.
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It is noticeable that cells in “Irrelevant IgG” control group produced lower
concentrations of IFN-and IL-10 compared to other control groups.

One possible

explanation is cross-linking of anti-His-tag antibodies. EAK16-II and EAKIIH6 coassembles into a fibrous network with His-tags appending on fibrils.

Anti-His-tag

antibodies have two Fab domains (binding sites). When each Fab binds to a His-tag on
two different fibrils, fibrils are efficiently cross-linked, resulting in a denser network with
smaller pores. The fibrous network functions as a barrier to migration of dAPCs, which
could be impeded when the network becomes denser.
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Figure 4-8 Concentration of IFN-γ and IL-10 produced by recipient C57BL/6 mouse
splenic T cells cultured with naïve BALB/c APCs. Treatments were administrated to
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the graft bed prior to the skin graft: αI-Ad membrane (EAK16-II, EAKIIH6, αH6-IgG,
pAG, and αI-Ad IgG), αI-Ad IgG, local (αI-Ad IgG in PBS), EAK16-II/EAKIIH6
(EAK16-II and EAKIIH6), Irrelevant IgG (EAK16-II, EAKIIH6, αH6-IgG, pAG, and
anti-I-Ab IgG), and Saline (isotonic saline solution). αI-Ad IgG, I.V. represents αI-Ad IgG
administrated through tail vein. Isograft indicates C57BL/6 to C57BL/6 transplantation.
(a) Schematic of the experimental procedures. 7 days after the transplantation, T cells
were prepared from spleen of recipient C57BL/6 mice and cultured with naïve BALB/c
mouse APCs.
The cell culture medium was collected by centrifugation and
concentrations of IFN-γ and IL-10 were quantified by ELISA. (b) Concentration of IFNγ produced by recipient C57BL/6 mouse splenic T cells. (c) Concentration of IL-10
produced by recipient C57BL/6 mouse splenic T cells. One way ANOVA with Tukey’s
multiple comparison was used for statistical analysis (n=5 for αI-Ad membrane, n=6 for
αI-Ad IgG, local, n=3 for EAK16-II/EAKIIH6, n=4 for αI-Ad IgG, I.V., n=3 for Irrelevant
IgG and saline, n=4 for Isograft, ***: p < 0.001, **: p < 0.01, *: p < 0.05, ns: not
significant, compared to αI-Ad membrane group,).
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Discussion
The two mouse strains tested here express distinct sets of class II MHC molecules: I-Ad
and I-Ed (BALB/c), and I-Ab (C57BL/6). These antigenic mismatches drive a robust
rejection regime. In C57BL/6 recipients, T cells exist to recognize I-Ad and I-Ed on
dAPCs to develop into IFN-driven cytotoxic responses. These reactions are sustained
by dAPCs (Figure 4-1). When placed in vivo, dAPCs migrate from skin explants to
stimulate recipient T cells in regional lymph nodes and ultimately populate the rest of the
host. The extent of anti-graft T cell activation correlates with MHC-II+ dAPCs migrated
to graft-draining lymph nodes (54). Donor MHC antigens (released by dead graft cells)
are also presented by graft-infiltrated host APCs (hAPCs). While this form of indirect
recognition contributes to rejection (7), the initial rejection intensity depends on dAPCs.
In spite of high dose calcineurin inhibitors (cyclosporine A and tacrolimus) and
corticosteroids, skin allografts are difficult to sustain owing to their heightened
antigenicity.

Attenuating acute rejection of skin-derived allogeneic antigens would

improve the viability and functions of such transplants as wound dressings. Localregional delivery of immunosuppressants was first attempted by Billingham in 1951
(162). Using cortisone acetate in a topical formulation the investigators were able to
prolong skin allograft survival in a rabbit model. Importantly, the same dose, which was
relatively low, was ineffective when administered systemically. The next documented
attempt came 35 years later when another group applied topical cyclosporine A (CSA)
formulated in DMSO to rats received skin allografts (163).

While long-term graft

survival was attained, interpreting results of the topical strategy was complicated by the
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large dose used (5 mg per kg daily).

The authors noted significant systemic drug

absorption. In general, the rationale for topical delivery of calcineurin inhibitors and
steroidal anti-inflammatory drugs are weakened by their lipophilicity and penetration
through the stratum corneum. Furthermore, Zhao and colleagues have reported bacterial
infiltrates in skin allografts of rats received topical CSA and fluocinolone acetonide (164).
Thus local drug delivery per se does not necessarily circumvent toxicities (165). Rather
than suppressing recipient leukocytes, depleting dAPCs may impute a targeted
mechanism to attain specific immunosuppression.
Depleting dAPCs in allografts has been explored as a potential anti-rejection therapy
previously. Odling and coworkers treated donor skins ex vivo with low-dose ultraviolet
light radiation or chemical carcinogens prior to grafting in mice to reduce dAPC activity
(166, 167). Depletion has also been done using anti-cell antibodies and genetically
engineered mice or precursor cells (153-155). Moreover, skin grafts live longer when
lymphatic drainage is temporarily impeded (168, 169).

These and similar methods

blocking dAPC trafficking are difficult to translate to humans. An unmet need is a
formulation by which trafficking of donor leukocytes can be intercepted in recipient hosts.
Herein evidence supporting a local strategy that builds upon self-assembling materials is

presented. The goal is to target unique cell surface molecules on donor immune cells that
drive acute rejection mechanisms.
The rejection of grafts correlates with the density of dAPCs; each dendritic cell (DC,
the most potent APC) is able to activate 100-3,000 T cells (170). Immature DC is 6-9 µm
in size, smaller than mature ones (15 µm) (171). Mature dendritic cells will upregulate
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the expression of MHC-II molecules, which increase from about 40,000 to 200,000 per
cell (172, 173). In skin transplantation, a skin graft of 0.5 cm × 1 cm was used, which
may contain about 50,000 dAPCs. An initial dose of 1.33 × 10-5 µmole antibodies (8 ×
1012 IgG molecules) were administrated, more than half of that could be considered to be
stably displayed as the fluorescent intensity on day 3 was still higher than half of the
initial fluorescence (Figure 4-6). The number of antibodies displayed (4 × 1012 IgG
molecules) exceeds the number of MHC-II molecules (4 × 1010). Therefore, the antidAPC membrane might be able to immobilize all dAPCs in theory.
The anti-dAPCs membrane was shown to form in situ, in both normal skins and on
transplant graft bed. The membranes remained in place for 6 days, exceeding the kinetics
of dAPCs emigration from ear skins, which peaks on day 5 in vitro (152). Attenuation of
allograft-specific T cell responses in recipients was demonstrated (Figure 4-8). Without
the I-Ad membrane system, T cells harvested from spleens strongly reacted toward
donor antigens, as evidenced by the high concentrations of IFN- produced ex vivo. But
mice treated with the I-Ad membrane showed general hypo-responsive T cells evident
in low IFN- and IL-10 production. Studies have shown that increased IL-10 would
indicate tolerance towards the allografts. Expansion of IL-10-producing regulatory T
cells would require inflammatory or immune modulation (174, 175). It should be noted
that all transplanted skins were rejected (scored based on gross necrosis) by day 10. This
was not unexpected given the extent of MHC disparities. In addition, the flow data
indicates some dAPCs were able to circumvent the αI-Ad membrane and reach the
draining lymph nodes. Therefore, some host T cells will still be activated through direct
119

allorecognition. Nevertheless, the data presented herein demonstrated the utility of an
anti-MHC-II material system in mitigating skin allograft rejection. Taken together, the
data support the hypothesis that anti-MHC-II membrane can attenuate acute rejection by
impeding trafficking of dAPCs to secondary lymphoid tissues.

Conclusions
The biological functionality, i.e. immune modulation, of the antibody display system has
been demonstrated in a murine skin transplantation model. In this model, the acute
rejection of allograft is mediated through emigrating dAPCs (MHC-II: I-Ad), which
activate T cells by direct allorecognition. Using NIR fluorescence dye labeled IgG,
antibodies could be stably displayed in the graft bed as well as subcutaneous space in
healthy mice. When anti-I-Ad IgG were displayed, the resultant anti-dAPCs membrane
was able to impede the trafficking of dAPCs to host draining lymph nodes. As a result,
systemic T cell responses were attenuated indicated by the lower production of IFN-γ.
The mouse skin transplantation (BALB/c to C57BL/6) is a stringent model widely
employed in development and validation of immunosuppressants (176). Mouse ear skin
contains high density of residing APCs, and the strength of acute rejection correlates with
number of dAPCs. For example, mouse ear skin is much more antigenic than mouse tail
skin as the latter contains very few LCs (152). Because of the distinctive mismatched
MHC-II molecules, we did not expect prolonged survival of graft from rejection.
However, our studies demonstrated the feasibility of attenuating host T cell activity by
intercepting migrating dAPCs.
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The antibody display system is versatile and injectable, and it may be transferred to
other transplantation models, such as liver and kidney transplantation. Mouse solid
organs also have a high number of DCs. For instance, heart, kidney, pancreas, and liver
of C57BL/10 mouse have 400,000, 650,000, 350,000, and 3,000,000 DCs respectively
(177), which results to strong acute rejections.

The anti-dAPC membrane may be

administrated at the graft-host interface. Compared to skin transplant, solid organs have
more blood supply and tissue fluid, which may accelerate the assembly process. A fully
assembled anti-dAPC membrane might capture dAPCs more efficiently considering the
fact that dAPCs starts to migrate within hours after the surgery.
Although it was not further pursued in my dissertation project, evidence of colocalization of anti-dAPC membrane and dAPCs would strengthen our conclusion that
trafficking of dAPCs was impeded. This may be achieved by pre-labeling dAPCs ex vivo,
for instance, using dual imaging nanoemulsions (178-180). Therefore, migration of
dAPCs could be tracked real time.
Besides acute rejection driven by dAPCs, hAPCs could also activate T cells after
uptake and presentation of donor antigens, i.e. chronic rejection (1). One advantage of
our system is versatility. Antibodies targeting different antigen could be co-displayed on
the membrane in situ. To translate this strategy into clinical therapies, it may be used in
combination with immune suppressants. Antibodies targeting cell surface molecules of
both dAPCs and hAPCs could be co-displayed. By disrupting the trafficking of APCs of
both traits, doses of immune suppressants may be reduced as well as unwanted side
effects.
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CHAPTER 5
Co-assembly of Amphiphilic Peptide EAK16-II with Histidinylated
Analogues and Implications for Functionalization of β-sheet Fibrils in
vivo
In Chapter 3 and Chapter 4, a prototype formulation of the antibody display system
(Table 1-2), which was developed based on pilot studies, was used to demonstrate in vivo
performance. To advance this system into clinical applications, the formulation has to be
fully optimized.

EAK16-II/EAKIIH6 co-assembly functions as the base of antibody

display system. Understanding how the two peptides co-assemble would provide insight
in optimizing the system in the future. As a step towards next stage development, the
EAK16-II/EAKIIH6 co-assembly was characterized and discussed in the current chapter.

Abstract
EAK16-II is one of first building blocks of environmental responsive materials. This
self-assembling peptide undergoes solution-to-gel transition when transferred from low to
high ionic strength environment. Previously we have demonstrated the histidinylated
analogue EAKIIH6 co-assembles with the parent peptide to render His-tags as a
functionalization mechanism in vitro and in vivo.

The present chapter aimed to

understand the pathways by which the analogue co-assembles with EAK16-II. The results
presented herein suggested two competing but not mutually exclusive events in the coassembly. Gel electrophoretic data showed that EAKIIH6 self-sorted to high molecular
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weight species without EAK16-II.

Spectroscopic analysis indicated that these high

molecular weight species consisted of both α-helices and β-strands.

Self-sorting of

EAKIIH6 was inhibited by the parent peptide in a concentration dependent manner.
Injecting mixtures containing EAKIIH6 subcutaneously rendered His-tags detectable in
live mice for at least 312 h, despite diluting the histidinylated analogue by 10 to 50 folds
compared to a previous formulation (4:1 in chapter 3). The study provided a formulation
by which in vivo display of His-tags was attained without excess amphiphilic peptides.
By increasing co-assembling efficiency, the likelihood of generating immunogenic
aggregates outside the main fibrils could be minimized. These findings provide insights
for rational functionalization of in situ self-gelling materials.

Introduction
β-sheet fibrillizing peptides are versatile building blocks of drug delivery systems and
tissue engineering scaffolds (38, 156, 181, 182). The EAK16 series of low molecular
weight peptides form cross- fibrils on which cell attachment and differentiation are
supported (57). These in situ-forming -fibrils can be functionalized for biomedical
applications (156). Bioactive amino acid motifs can be synthesized in tandem with selfassembling domains while preserving self-assembly and hydrogelation through ioniccomplementarity (28).

This strategy has been used to control cell attachments by

embedding within amphiphilic sequences with biological ligands (27, 34). An alternative
approach is to drive co-assembly of two ionic complementary peptides of which one
contains a functional domain (50, 123, 183, 184). An advantage of this approach is that
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the bioactive motif is structurally decoupled from the fibrillizing domain, thereby
allowing mutual optimization of both traits.
We have previously characterized the properties and functions of cross- fibrils
formed by admixing EAK16-II with its C-terminal histidinylated analogue EAKIIH6.
Both peptides contain an amphiphilic domain with alternating hydrophilic and
hydrophobic amino acids. The ionic-complementarity drives co-assembly of the two.
Introducing His-tags provides a versatile docking mechanism; it transforms the
fibrillizing module into a platform on which diverse therapeutic proteins can be anchored
via nickel coordination or non-covalent protein-protein interactions. We have previously
demonstrated utility of the latter using anti-His-tag antibodies (H6-IgG) and protein
A/G (pAG).

The specificities and high affinities of anti-His-tag antibodies for

consecutive histidines and pAG for IgG Fc domain collectively render a reliable linking
regime. Displayed antibodies proved biologically active. When injected into living mice
the antibody-material assemblies remain stable at the injection site for at least 5 days.
We envision this system can be used for modulation of local immune milieu at the same
time minimizing systemic toxicities. Antibodies targeting soluble antigens or cell surface
markers can be localized in tumors or other inflammatory locales to steer immunological
reactions toward favorable outcomes (chapter 3 and 4).
The low viscosity of the peptide-protein mixture in deionized water allows injection
via conventional needled syringes.

In our experimentations, the two peptides were

intermixed in deionized water before fibrillizing in salt solutions or in vivo. Gasiorowski
and Collier showed such mixing sequence results in gels with superior cell adhesion
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capacity in vitro (185). In their study, Q-11-based peptides (sequence: QQKFQFQFEQQ)
were formulated in 10:1 molar ratio, with functionalized (RGD) peptide as the lesser of
the two. In our studies, when formulated at 4:1 molar ratio, the EAK16-II/EAKIIH6 coassembly stably displays His-tags in vitro (50). When injected into mice subcutaneously,
the same formulation localizes His-tags at the injection site for up to 11 days (Figure 3-6).
An advantage of employing the co-assembly strategy is that His-tags (EAKIIH6) can
be introduced into emergent materials without compromising gelation (EAK16-II). The
ability to tune the amount of His-tags independently provides a way to tailor the design
for specific applications. However, the notion that His-tags can be optimized by simply
changing the relative fraction of EAKIIH6 warrants close examination. The efficiency of
the co-assembly depends on two competing but not mutually exclusive events: EAKIIH6
may associate with other EAKIIH6 molecules (self-sort), and/or with EAK16-II (coassembly).

Based on molecular modeling studies it was postulated that EAKIIH6

intercalates into EAK16-II -sheets (50). The present study aimed at understanding the
mechanisms by which EAKIIH6 are driven into EAK16-II fibrils. The co-assembling of
EAK16-II and EAKIIH6 in vitro and in vivo was interrogated experimentally in this
chapter. Insights gained from in vitro studies guided in vivo delivery formulation efforts.
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Materials and Methods
Peptides and reagents
All peptides were custom synthesized by American Peptide Company (Sunnyvale, CA) at
greater than 95% purity with termini acetylated or amidated. Peptides were reconstituted
in sterile MilliQ water (18.2 M at 25C) at 5 mg/mL (3 mM, EAK16-II, AcNHAEAEAKAKAEAEAKAK-CONH2) or 7.5 mg/mL (3 mM, EAKIIH6 or EAKIVH6:
AcNH-AEAEAEAEAKAKAKAKHHHHHH-CONH2), or 7.2 mg/mL (3 mM, VHAH6:
AcNH-VHASHAVHAAHAVHAHHHHHH-CONH2).

Rabbit anti-His-tag polyclonal

antibody (αH6-IgG, 0.2 mg/mL) and fluorescein conjugated Rabbit anti-His-tag
polyclonal antibody (αH6-IgGFITC, 0.2 mg/mL) were purchased from AnaSpec, Inc (San
Jose, CA). DyLight 800 conjugated goat anti-rabbit IgG (Rabbit-IgG800; 1 mg/mL) was
purchased from Pierce Biotechnology (Rockford, IL).

Gel electrophoresis
SDS-PAGE was used to probe whether EAKIIH6 would precipitate. The peptide was
dissolved in PBS at 0.0015, 0.003, 0.006, 0.015, 0.03, or 0.06 mM. Supernatants were
analyzed using denaturing conditions in NuPAGE 4-12% Bis-Tris gels (Life
Technologies, Carlsbad, CA) before and after centrifugation (relative centrifugal force
(rcf) = 16,000g for 10 min).

Peptide aggregates were identified using native gel

electrophoresis. EAKIIH6 (0.015 μmol in 5 μL) was added to 45 μL of PBS buffered at
different pH for 2 h at 37C. Supernatants were run on NativePAGE 4-16% Bis-Tris gel
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(Life Technologies). To quantify the co-assembly efficiency, 0.015 μmol (in 5 μL) of
EAKIIH6 (or EAKIVH6 or VHAH6 as related analogues for comparison) was mixed
with 4, 8, 16 or 32-folder higher moles of EAK16-II before adding into PBS to a final
volume of 500 μL. EAKIIH6 (0.015 μmol) alone was included as a standard. After
incubation at room temperature for 2 h allowing for precipitates to settle under gravity,
supernatants were analyzed using denaturing NuPAGE 4-12% Bis-Tris gel (Life
Technologies). Proteins were visualized using SilverQuest staining (Life Technologies)
with a reported detection limit of 0.3 ng. Images were taken using the Kodak 440 Image
Station (Rochester, NY) and band intensity was quantified using ImageJ (version 1.45s).

Fluorescent measurement and microscopy
To probe His-tag accessibility, 0.12 μmol (in 40 μL) of EAK16-II was mixed with
different amounts of EAKIIH6 (or EAKIVH6 or VHAH6) to generate different ratios of
the two. The premixed peptide solution was added PBS to a final volume of 1 mL into
which 20 μg of αH6-IgGFITC was added. Co-precipitates were rinsed and collected by
centrifugation at 15,000g for 10 min. The pellets were then transferred to a 96 well plate
in which fluorescent intensity was measured using a Perkin Elmer VICTOR 1420 reader
(Perkin Elmer, Waltham, MA). Images of the same samples were captured using a Vista
Vision inverted microscope (VWR, Radnor, PA) equipped with a ProgRes C3 cooling
CCD camera (Jenoptik AG, Jena, Germany).
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Spectroscopic analyses of peptide conformations
Fourier-transformed infrared (FT-IR) spectroscopy was performed using desiccant-dried
samples of 0.06 μmol (in 20 μL) EAKIIH6 dissolved in 80 μL of PBS. FT-IR spectra
were recorded on a Thermo Nexus 470 Infrared Spectrometer using an attenuated total
reflectance (ATR) cell operated at a spectral resolution of 4 cm-1 over 256 scans. The
spectra were processed in OMNIC software (Thermo Scientific) for automatic baseline
correction and smoothing, after which the second derivative was calculated. To obtain
the CD spectra, 0.015 μmol (in 5 μL) of EAKIIH6 was added into 195 μL PBS with
different pH: 1, 3, 5, 7, 9, and 11. After 2 h incubation at room temperature, CD spectra
of samples were recorded from 180 nm to 260 nm on a Jasco J-810 spectropolarimeter
(Jasco Analytical Instruments, Germany). The signal was collected on 0.1 nm intervals
and averaged by 7 runs. After background correction, absorbance values were converted
to mean residue ellipticities. Percentage of secondary conformations was evaluated using
CDPro algorithms (186) based on reference protein data set no. 3.

The results

represented an average of three deconvolution algorithms (SELCON3, CONTINLL, and
CDSSTR).

Mice and in vivo clearance
Six to eight week old female (certified-virus-free) BALB/c mice were purchased from
Charles River Laboratories (Wilmington, MA) and housed in the Duquesne University
Animal Care Facility. Animals were handled in accordance with protocols approved by
University Institutional Animal Care & Use Committee. The injection mixtures contained
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0.12 μmol (in 40 μL) of EAK16-II added with different ratios of EAKIIH6 (or EAKIVH6
or VHAH6). In a separate vial, 20 g of a rabbit-derived αH6-IgG was mixed with 20 g
goat anti-rabbit Dylight-800 conjugated IgG. The two mixtures were drawn into the
same syringe (28 G’ needle) and injected subcutaneously into the lower flank of mice.
Abdominal hairs were removed prior to imaging using a Pearl Impulse imager (Li-Cor,
Inc.) while mice were anesthetized with isoflurane (induction 5%, maintenance 3%). All
images were captured at the same threshold and resolution (170 µm) settings. Ovalshaped regions of interest were defined at the site of injection with contralateral flank as
background. Fluorescence intensity was quantified using the Impulse software (Li-Cor,
Inc.) with a standard deviation multiplier of 10 and a search limit of 100 pixels.

Statistical analysis
Statistical analysis was performed in GraphPad Prism 5.0. Data were analyzed using
one-way ANOVA and the Tukey-Kramer pairwise multiple comparison test (α=0.05).
Data shown represent mean and standard deviation. Power analysis is used to determine
the sample size of the in vivo studies (n=4). For comparison of mice treated with
EAK16-II, EAKIIH6, PBS, or EAK16-II/EAKIIH6, an n of 4 yields 1-β greater than 0.99.
n indicates number of replicates/animals in each group.
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Results
Self-sorting of EAKIIH6
Understanding the competing events of co-assembly and self-sorting (either selfassemble into fibrils or form unordered aggregates) is imperative for rational design of
multi-component fibrillar materials. It has been shown that EAKIIH6 by itself was not
able to self-assemble into macroscopic fibrous structures both in vitro (Figure 3-2c) and
in vivo (Figure 3-7). As expected, high-density materials were not found in EAKIIH6
below or above the critical assembling concentration (CAC) of EAK16-II (CAC = 0.1
mg/mL) (72); all peptide dissolved at 1.5-60 M in PBS remained in supernatants after
centrifugation (Figure 5-1a). Although no insoluble macroscopic structure had been
observed, native gel electrophoretic data revealed that EAKIIH6 at a concentration of 0.3
mM formed oligomers in acidic, neutral and alkaline buffers (Figure 5-1b); multiple
species weighing between 240 to 480 kDa and beyond 720 kDa were found in nondenaturing gels. These aggregates corresponded to from 100 to 300 EAKIIH6 peptides
(MW = 2.48 kDa). These data revealed the intrinsic propensity of EAKIIH6 to self-sort
into multimeric structures.

Nonetheless, EAKIIH6 was not able to form insoluble

membrane by itself even at high pH. His-tags would disrupt the hydrophobic interactions
of alanines if they are part of stacked β-sheets, therefore, they may have to extrude
outwards of β-sheet. On the other hand, these appending His-tags could still destabilize
EAKIIH6 β-sheets due to steric expulsion.
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Figure 5-1 Non-precipitation and self-sorting of EAKIIH6. (a) Denaturing PAGE of
supernatants from EAKIIH6 buffered saline samples centrifuged (“C”; 16,000 rcf) and
non-centrifuged (NC); (b) Native PAGE image of EAKIIH6 dissolved in PBS (0.3 mM)
after incubation. Figure adapted from reference (187) with permission.
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Conformations of EAKIIH6
We next determined if the EAKIIH6 species revealed in native PAGE were -fibrils. We
have previously shown that the amyloid-specific chromogenic dye Congo red fails to
bind EAKIIH6 (Figure 3-2c). To probe the nature of these higher-ordered structures,
ATR FT-IR was used to determine the peptide conformational ensemble in air-dried
samples of EAKIIH6 dissolved in PBS. Second derivatives revealed the presence of helix structure as indicated by the peak at 1649 cm-1. The peaks at 1630 cm-1 and 1622
cm-1 revealed the presence of β-strands and -sheets (Figure 5-2a) (188, 189). These
spectral features resembled those found in the spectra of EAK16-II, but the peak at 1622
cm-1 was weaker in the EAKIIH6 spectrum. The intense peaks at 1641 cm -1 and 1670
cm-1 in the EAKIIH6 spectrum suggested the presence of unordered structures and βturns, respectively. The dominance of -helix in EAKIIH6 was supported by circular
dichroism in which spectrum of the peptide showed double minima at 208 and 222 nm,
typical of -helix conformation. Intensities of these transitions changed at varying pH
(Figure 5-2b). Deconvolution revealed dominant -helix (~35%) between pH 1 to pH 7
(Figure 5-2c). The pattern reversed when pH rose above 9, at which -strand increased
to 22%, apparently at the expense of -helix (26%). The -helix to -sheet transition
coincided with deionization of the histidines. Most of the imidazoles (assumed histidine
pKa = 6.10) would be unionized at pH 9.
While the CD data indicates α-helix was the dominating conformation for EAKIIH6, a
stronger peak at 1622 cm-1 (compared to 1649 cm-1) in FT-IR spectrum implies a
relatively higher content of β-strand conformation.
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This difference may arise from

different sample preparation protocols.

CD spectrum was collected with EAKIIH6

dissolved in PBS which reflects conformations in solution states. In FT-IR studies,
peptides were incubated in PBS first and dried. As water is being removed, peptides may
re-organize to different structures. Nonetheless, these data suggested a plasticity of
EAKIIH6 conformational ensemble in which -helix and -strand coexisted.

The

findings supported a previous postulation that while EAKIIH6 generally adopts a -helix
conformation, it could be forced into -strands (50).
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Figure 5-2 Conformational properties of EAKIIH6 aggregates.
(a) Second
derivative FT-IR spectra of desiccant-dried EAKIIH6 and EAK16-II dissolved in PBS
(0.6 mM); (b) circular dichroism spectra of EAKIIH6 (0.075 mM) at different pH;
absorbance values were converted to mean residue ellipticities. (c) Percent α-helix and βstrand of EAKIIH6 revealed by deconvolution using CDPro. Figure adapted from
reference (187) with permission.
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Dilution of EAKIIH6 in EAK16-II
The observation that EAKIIH6 self-sorted into higher-ordered species instructed how the
peptides were formulated for in vivo applications. We postulated that at above a certain
relative amount, EAK16-II inhibits self-sorting of EAKIIH6, providing a rationale for
maximizing co-assembly efficiency.

To test this, the extent of co-assembly was

examined by mixing the two at different molar ratios. The fraction of EAKIIH6 was held
constant while varying EAK16-II, with the latter added at 4, 8, 16 and 32-fold higher
concentrations. Co-assembled peptides would precipitate and un-incorporated peptides
would remain in supernatant. Using SDS-PAGE it was found that at all ratios tested, no
EAK16-II was detected in the supernatant and therefore precipitated completely (data not
shown). Diluting EAKIIH6 with EAK16-II increased the efficiency of the co-assembly
(Figure 5-3a). At relatively low excess of EAK16-II (4:1 and 8:1), less than 40% of
EAKIIH6 co-precipitated into fibrils. Raising EAK16-II amount to 32:1 resulted in close
to 95% of EAKIIH6 precipitating (Figure 5-3b). These data indicated that the presence
of abundant EAK16-II inhibited self-sorting of EAKIIH6. Increasing the relative amount
of EAK16-II increased the efficiency of co-assembling.

Taken together, excess

EAKIIH6 in the low efficient mixtures (4:1 and 8:1) most likely diverted into aggregating
byproducts outside the main fibrils generated from co-assembly.
Two other His-tagged peptides were studied for comparison (Figure 5-4a). When
mixed with EAK16-II, VHAH6 co-precipitated poorly (Figure 5-3c). VHAH6 was shown
in circular dichroism adopting random coils in neutral phosphate buffers (Figure 5-4b).
The incorporation at higher EAK16-II ratios (16:1 and 32:1) may result from non-specific
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entrapment and adsorption of VHAH6 aggregates. Conversely, EAKIVH6 incorporated
efficiently with EAK16-II (Figure 5-3d).

This peptide adopted a weak -helix

conformation (Figure 5-4b), although the parent EAK16-IV adopts a hairpin/-turn
configuration, owing to intra-peptide charge pairing (67). The offset in charge patterns in
the amphiphilic segment between EAK16-II (--++--++) and EAKIVH6 (----++++) did
not preclude their co-precipitation (Figure 5-3d). These data indicated that peptides
containing amphiphilic domain in -helical conformation could participate in
fibrillization. Ionic pairing among -sheets in the fibrils appeared flexible. EAKIVH6
could slide along the EAK16-II -sheet horizontal plane to locate lateral hydrogen bonds
while minimizing charge repulsion.
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Figure 5-3 Co-assembly efficiency as a function of molar ratios of EAK16-II to
histidinylated peptides. (a) Representative image of unincorporated EAKIIH6 from
mixing with EAK16-II; co-assembly efficiencies EAKIIH6 (b; n=4), VHAH6 (c; n=2);
EAKIVH6 (d; n=2) with EAK16-II. A constant amount of histidinylated peptide
(EAKIIH6, EAKIVH6 or VHAH6) was mixed with increasing ratios of EAK16-II before
injecting in a larger volume of PBS to trigger fibrillization. Samples were allowed to
settle under gravity prior to gel electrophoresis. Peptides were visualized using silver
staining. Band intensity was quantified using ImageJ. One way ANOVA and Tukey’s
multiple comparison test were used to confirm statistical difference (ns: not significant;
**: p<0.01, ***: p<0.001, compared to molar ratio 32:1). Figure adapted from reference
(187) with permission.
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Figure 5-4 Amino acid sequences and conformations of His-tagged peptides studied.
(a) Molecular structures of EAK16-II and histidinylated peptides. Peptides are presented
in β-strand conformation (Molecular Operating Environment; gray: carbon, red: oxygen,
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blue: amine, light gray: hydrogen). EAK16-II has a distinctive amphiphilic pattern. The
hydrophobic face consists of the alanine side chains and the hydrophilic face has the
glutamic acid and lysine side chains. At neutral pH, all glutamic acids and lysines are
ionized. (b) Circular dichrotic spectra of EAKIVH6 and VHAH6. Each peptide was
dissolved in PBS at 0.075 mM. Figure adapted from reference (187) with permission.
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In vitro His-tag accessibility
Having established the threshold (32:1) beyond which co-assembly occurred at above 95%
efficiency, we next studied His-tag accessibility. Near complete incorporation could be
assumed in these systems of EAK16-II-diluted EAKIIH6 (40:1, 80:1 and 200:1).
Accessible His-tags were detected using a fluorescein-conjugated anti-His-tag antibody
(H6-IgGFITC). In these and studies described hereafter, the amount of EAK16-II was
held constant while varying EAKIIH6 in the mixtures. This was done to maintain nonspecific binding relatively constant. All groups containing EAKII-16 and EAKIIH6
exhibited fluorescence.

No significant difference was observed in co-precipitates

prepared at ratios 40:1 and 80:1, but the fluorescence in 200:1 was reduced significantly
(Figure 5-5a). Direct imaging of the precipitates confirmed the differential binding of
H6-IgGFITC (Figure 5-5b).

His-tag detection was specific; only near background

fluorescence was observed in fibrils formed with EAK16-II without EAKIIH6 (Figure 55b: “EAK16-II”). Weak fluorescence was observed in precipitates formed by admixing
EAK16-II with the non-complementary VHAH6, in which no accessible His-tags were
appended on the fibrils. On the other hand, EAKIVH6 incorporated efficiently with
EAK16-II, rendering strong fluorescence in the co-precipitates. These data recapitulated
results of the co-assembly studies (Figure 5-3) and demonstrated that higher amounts of
EAKIIH6 would not necessarily generate more accessible His-tags.
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Figure 5-5 Detection of accessible His-tags in co-assemblies in vitro. (a) Average
fluorescent intensity samples containing EAK16-II admixed with EAKIIH6 (or
EAKIVH6 or VHAH6; n=3). (b) Fluorescent micrographs of co-assemblies incubated
with αH6-IgGFITC. Peptides dissolved in PBS were incubated with αH6-IgGFITC with
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unbound antibodies removed by washing centrifugation. One-way ANOVA and Tukey’s
multiple comparison test were used to determine statistical difference (“ns”: not
significant; **: p<0.01, ***: p<0.001, compared to 80:1 EAK16-II/EAKIIH6). Figure
adapted from reference (187) with permission.

142

In vivo His-tag accessibility
Our previous in vivo studies showed prolonged localization (up to 11 days) of His-tag
functionalized EAK16-II fibrils when a high relative amount of EAKIIH6 (4:1) was used
(123). It was thought that stable co-assembly in the subcutaneous space would require
abundant EAKIIH6 due to limited mixing of fluid and salts. To examine this supposition,
mixtures with diluted EAKIIH6 (40:1, 80:1 and 200:1) were injected subcutaneously into
the posterior flank of BALB/c mice. His-tags were adapted with H6-IgG to form a
platform onto which protein A/G and model therapeutic antibodies could be loaded. In
the present study, the stability of the tri-component assemblies (EAK16-II, EAKIIH6,
and H6-IgG) was monitored using a NIR dye (=800 nm)-labeled anti-rabbit antibody
(Rabbit-IgG800) that binds to the rabbit-derived H6-IgG. At all ratios tested, the NIR
dye-labeled antibody remained at injection site for at least 312 h (Figure 5-6). The initial
rapid fluorescence decline (5 min to 24 h; Figure 5-6d) could be attributed to limited
mixing in the subcutaneous space. EAK16-II self-assembling requires at least 20 mM of
NaCl (71). The lag-time for peptides mixing with critical concentrations of salts would
result in loss of unbound antibodies (H6-IgG and Rabbit-IgG800) to lymphatic
drainage.
After the initial phase, the formulations performed differently. From 48 h to 168 h,
mice injected with the peptides at 40:1 and 80:1 ratios (Figure 5-6a&b: “II” & “III”)
rendered at least two-fold higher fluorescence compared to those which received only
EAK16-II (Figure 5-6a&b: “I”).

Fluorescence generated by injecting mixtures at 40:1

and 80:1 remained above background from 168 h to 312 h.
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Injecting the mixture

formulated at 200:1 yielded slightly lower fluorescence (Figure 5-6a&b: “IV”), although
the intensities at all time-points were not significantly different from those in mice
received 40:1 and 80:1 mixtures (Figure 5-6b). Differential retention of the His-tagged
fibrils was evidenced in the respective AUC24h- (Table 5-1). These results indicated that
the peptides rendered functional His-tags in living mice, despite diluting the
histidinylated analogue by 10 to 50 folds.
There are three phases in fluorescence decay of antibodies from EAK16-II (Figure 5-6:
“I”). The intial rapid decrease of fluorescent intensity may be caused by diffusion of
antibodies at the periphery and those able to diffuse out via large pores. The plateau
phase might correspond to antibodies trapped in smaller pores. The residual decline
phase could possibly result from fragmentation/dissociation of the membrane, which
would release antibodies trapped inside. The similar fluorescence decay profiles in the
residual phase (192 h – 336 h) of His-tagged membranes (Figure 5-6: “II”, “III”, and
“IV”) may be attributed to diffusion of antibodies after fragmentation of membranes.
His-tagged membranes were able to retain higher concentration of antibodies because of
the non-covalent interactions between His-tags and antibodies. However, anti-His-tag
antibodies would dissociate from His-tags and fluorescence labeled secondary antibodies
would also dissociate from anti-His-tag antibodies eventually. Antibodies fall off the
His-tagged membrane would diffuse out the fibrous network similar to non-specifically
encapsulated antibodies in the EAK16-II membrane (“I”). Similar diffusion processes
led to similar fluorescence decay profiles in residual phases.
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Injecting H6-IgG and Rabbit-IgG800 alone resulted in fluorescence dissipating to
near background at 96 h (Figure 5-6a&b: “VIII”). At the same time point, only marginal
retention was seen with EAKIIH6 alone (Figure 5-6a&b: “VII”); AUC24h- of the
fluorescence amounted to less than 20% of that in the most diluted EAK16-II/EAKIIH6
(200:1; Table 1). These data were consistent with previous observations that without
EAK16-II, EAKIIH6 localizes poorly in vivo. In congruent with results of the His-tag
accessibility studies in vitro (Figure 5-5), co-administration of EAK16-II and VHAH6
(80:1) yielded weak fluorescence in vivo (Figure 5-6a&c: “VI; Table 5-1). In contrast,
injecting a mixture (80:1) of EAK16-II/EAKIVH6 resulted in sustained fluorescence
lasting up to 312 h at intensities comparable to mice receiving EAK16-II/EAKIIH6
(Figure 5-6a&c: “V”). These data indicated a selective but tolerant mode of EAK16-II sheets as acceptors of amphiphilic peptides.
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Figure 5-6 In vivo real-time detection of His-tags in formulations with diluted
EAKIIH6.
Solutions containing the peptides, H6-IgG and Rabbit-IgG800 were
injected into lower flank of BALB/c mice subcutaneously. Fluorescent intensity was
quantified using the Pearl Impulse (v2.0) software. (a) Representative images of mice
injected with antibodies and EAK16-II (“I”), or EAK16-II/EAKIIH6 (40:1; “II”), or
EAK16-II/EAKIIH6 (80:1, “III”), or EAK16-II/EAKIIH6 (200:1; “IV”), or EAK16II/EAKIVH6 (80:1, “V”), or EAK16-II/VHAH6 (80:1, “VI”), or EAKIIH6 (“VII”).
“VIII” represents mouse injected with αH6-IgG and αRabbit-IgG800 alone in PBS. All
images were exported with the same settings from Licor Pearl Impulse. Time-lapse
fluorescence was monitored in mice injected with (b) different ratios of EAK16-II to
EAKIIH6 and (c) EAKIVH6 or VHAH6 at 80: 1 molar ratio. “I” and “III” were repeated
in panel (c) for comparison. n=4 for all groups except n=5 for group III&VI and n=3 for
group VIII. Figure (d) shows the fluorescent decay of all groups in the first 24 h. The
transient increase in fluorescent intensity in the first 6 h was attributed to an artifact.
Immediately after injection the local fluorescence exceeded detection threshold. Over the
next few hours, the NIR-dye labeled antibody (Rabbit-IgG800) diffused to surrounding
tissues, resulting in an expanded area of fluorescence of which the intensity was already
saturating. Figure adapted from reference (187) with permission.
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Table 5-1 Peptide formulations used for determining His-tag retention (AUC) in vivo.
: molar ratio of EAK16-II to EAKIIH6 or control analogue; total volume of peptides and
antibodies injected = 90 µL. *: Area-under-the-curve (AUC) of fluorescence in mice
beginning at 24h after subcutaneous injection of EAK16-II/EAKIIH6, H6-IgG, and
Rabbit-IgG800; FI: fluorescent intensity. Table adapted from reference (187) with
permission.
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Discussion
We sought to understand the molecular events driving co-assembly of two ioniccomplementarity peptides, one of which contains a C-terminal His-tag. The goal was to
maximize co-assembly efficiency such that display of His-tags as protein anchors could
be optimized. Ideally all components should be driven into the fibrillar assemblies with
no fringe aggregates. Functionalized amphiphilic peptides generally retain the capacity
to self-sort, either into fibrillar materials (with or without a co-assembling peptide) as
intended, or into amorphous/bundled aggregates as byproducts.

Dendritic cells and

macrophages would take up byproducts aggregating into particulates.

The ensuing

peptide-specific antibody responses would result in material failure, but could also trigger
autoimmune complications (190).
In the current study, we found that self-sorting of EAKIIH6 competed against coassembly (Figure 5-7). Excess EAKIIH6 in low efficient mixtures (4:1 and 8:1) most
likely diverted from co-assembly into non-fibrillar aggregates. Self-sorting of EAKIIH6
could be driven by bundling of the peptide in helical conformation; the large dipole
moment of EAKIIH6 -helix would diminish (14023 debye, Wen and Meng) when
dimerized in anti-parallel fashion. This self-sorting appeared inhibited by EAK16-II in a
concentration-dependent manner.

With these in mind, we tested peptide mixtures

containing diluted amounts of EAKIIH6. It was determined that even when diluted at 40,
80 and 200-fold, mixing the two peptides resulted in co-assemblies with accessible Histags in vitro and in vivo. Localized His-tags were detectable in living mice for more than
12 days, comparable to formulations at which a larger amount of EAKIIH6 (4:1) was
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used. The ability to retain His-tags in vivo for extended duration affords opportunities for
high dose, local delivery of therapeutic proteins.
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Figure 5-7 Proposed pathways of EAKIIH6 incorporation into EAK16-II fibrils.
EAKIIH6 conformational ensemble contains peptide in -helix, -strand, random coil,
and other secondary structures. In the absence of EAK16-II or other strong -fibrillizing
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peptides, EAKIIH6 self-sorts into dimers, oligomers, and high molecular weight species.
EAK16-II functions as a template; diluting EAKIIH6 in EAK16-II facilitates coassembly. In the presence of EAK16-II, helical EAKIIH6 transition into β-strands that are
stabilized within fibrillizing EAK16-II β-sheets. Co-assembly efficiency depends on
extent of excess EAK16-II. With large excess of EAK16-II, all EAKIIH6 are captured
into the fibrils. With low excess of EAK16-II, EAKIIH6 molecules are partially
incorporated, with some peptides self-sorted into oligomers. Figure adapted from
reference (187) with permission.
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EAKIIH6 naturally adopts -helix conformation (50).

This is consistent with

Armstrong and Baldwin’s analysis that C-terminal histidines drive oligopeptides into helix conformation (191). Alpha-helix is stabilized by intra-peptide hydrogen bonds
between ith amine group and i+4th carbonyl group. The four amines groups (positive) in
the N-terminal and four carboxyl groups (negative) in the C-terminal are un-hydrogen
bonded, which produces a dipole moment (192). Histidines (pKa ~ 6.5) are charged at
acidic pH and partially charged at neutral pH, which stabilize α-helix by counteracting
with the dipole moment. Raising the pH appeared to relax the stabilizing effect on helix as more charged histidines were unionized.

On the other hand, -strand

conformation was also found in the ensemble of conformations. In the presence of
EAK16-II, helical EAKIIH6 could conform to the -strand conformation by hydrogen
bonding with stacked -sheets in the emergent fibrils. Helix-to-strand conversion has
been documented extensively in protein-protein oligomerization (193-195). Formation of
amyloidal proteins has been shown to be initiated by template-driven conformational
change. Gobbi et al have described a “dock-and-lock” model of prion protein (PrP82–146)
fibrillization in which the locking step entails sequential conformational changes (35,
196). The plasticity of EAKIIH6 conformation would facilitate such docking.
In the mixing regime of EAK16-II/EAKIIH6 used herein, self-sorting or fibrillization
of each was suppressed by keeping the ionic strength low in the initial water mixtures.
Upon transferring to high ionic strength phosphate buffers, the rapid (within 10 seconds
based on Congo red binding) self-assembling of excess EAK16-II captured EAKIIH6
molecules. EAKIIH6 appeared to form oligomers (Figure 5-1b) that could be entrapped
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in the EAK16-II network en masse, thus removable from supernatant. A portion of the
resultant bundled histidines may be inaccessible.

Anti-His-tag antibodies generally

recognize epitopes containing at least three or four consecutive imidazoles. The finding
that 40:1 and 80:1 showed the same His-tag availability in vitro and stability in vivo
supported the notion that a fraction of the histidines in the 40:1 formulation was buried.
Thus, the current study identified 80:1 (EAK16-II to EAKIIH6) as the optimum; at this
ratio stable His-tagged co-assemblies were generated at high co-assembly efficiency.
Altering the sequence of mixing changed the incorporation efficiency; mixing EAKIIH6
and EAK16-II that were separately assembled in PBS resulted in poor co-assembly
efficiency (<52% at 32:1; <18% at 16:1; 0% at 8:1 and 4:1). In this case, the fast kinetics
of EAK16-II self-assembling induced by salts in the first step resulting in exclusion of a
large fraction of EAKIIH6 in the second.

Conclusions
The current study showed that in vivo co-assembly of the two ionic complementarity
peptides could be guided by in vitro optimization. The histidinylated analogue EAKIIH6
exhibited malleable conformations. Histidines become deprotonated at basic pH, which
might induce conversion of α-helix to β-strand. Self-aggregation of EAKIIH6 could be
inhibited by the parent peptide in a concentration dependent manner. Near complete
incorporation was observed at a molar ratio of 32:1 (EAK16-II: EAKIIH6). At lower
ratios, EAKIIH6 may be excluded from the assembly.

Consistent with in vitro

characterization, diluted formulations were shown to form stable His-tagged membranes
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in vivo. The study revealed a formulation by which in vivo display of His-tags was
attained without excess amphiphilic peptides.

Aggregates from excessive EAKIIH6

could be problematic. Studies have shown that protein aggregates augment immune
response because of crosslinking of B cells by repetitive structures (197, 198). Antipeptide antibodies would compete for binding sites and accelerate the clearance of Histagged membrane.

By increasing the efficiency of co-assembly, the likelihood of

generating immunogenic aggregates outside the main fibrils could be minimized.
It was proposed that EAKIIH6 adapts β-strand conformation and co-assembles with
EAK16-II with the “EAK” domain. This model requires further validation in the future.
CD and FT-IR only revealed overall conformations instead of the conformation of
individual peptide.

Incorporation studies using SDS-PAGE also did not provide

information on orientation and location of EAKIIH6. High resolution techniques, such as
solid state NMR with isotope labeling, may be used to fully understand the co-assembly
(75).
Besides His-tag, non-ionic linkers might be employed. Self-assembling peptides were
functionalized with biotin, which display biotinylated functional motifs via streptavidin
(96). Incorporation of functionalized peptides with small non-ionic linker may require
less parent peptide because of the absence of repulsive forces. While His-tag provides an
anchoring mechanism for displaying functional domain (123), direct conjugation of
functional proteins has also been documented. When appended with repeating units of
AEAEAKAK, the fluorogen-activating protein (FAP) L5 (a 25 kDa single-chain variable
fragment (199)) can be incorporated into EAK16-II fibrils (184). The design renders
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FAP displaying fibrillar materials on which the weak fluorescence of the fluorogen
malachite green is enhanced exponentially.
Although not specifically determined in the current study, cytotoxicities of EAK16
analogues have been studied by Zhang and coworkers (34, 183). Materials from these
peptides have been used successfully as 3D cellular scaffolds and other applications. In
our experiences, EAK16-II/EAKIIH6 fibrils are compatible with epithelial cells and T
cells (52). Taken together, the data presented herein demonstrated that co-assembly is a
versatile strategy for functionalization of fibrils made of ionic complementary peptides.
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CHAPTER 6
Summary and Future Directions
Because of the high specificity and affinity to their target antigens, mAbs represent an
important and attractive class of immunotherapy in cancer, transplantation management,
and autoimmune diseases. However, severe side effects have been reported due to lack
of specificity at tissue/organ level. To improve the therapeutic outcomes of mAb, we
have developed an injectable, biocompatible, and versatile antibody display system using
the self-assembling peptides, EAK16-II and EAKIIH6. Antibodies targeting soluble
antigens or cell surface molecules are all capable of being loaded. Proof of concept
characterization studies indicate that antibodies could be stably displayed in subcutaneous
space and tumor tissue for at least 120 h. When anti-dAPC antibodies were displayed,
the trafficking of dAPCs was impeded and the host immune activity was attenuated in a
mouse skin transplantation model. The peptide co-assembly had been systematically
investigated. His-tagged peptide may adopt β-strand conformations and align with the
existing amphiphilic parent peptide β-sheets to provide accessible and tunable His-tags.
Taken together, the performance of antibody display system had been demonstrated and
the peptide co-assembly had been characterized. Our findings suggest the antibody
display system would be a promising platform in improving the therapeutic outcomes of
mAb.
To translate the antibody display system into clinical applications, further
characterization is a prerequisite.

A stepwise optimization will help us define a

formulation that provides stable antibody display without excessive peptides and proteins.
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Further characterization of the system may allow us to control density and dose of
antibodies displayed.
The in vivo fate of the antibody display system warrants closer examinations.
Although our data indicate antibodies could be retained at the site of injection for at least
5 days, the mechanisms of antibody clearance could not be concluded. The antibody
display system consists of five components and is stabilized by non-covalent interactions.
Although the affinity among linker proteins is relatively high, it may still dissociate. Histagged membranes may break down to small fragments. Another complicating factor is
the competing binding from intrinsic antibodies. For example, these antibodies may
compete for pAG, resulting in accelerated clearance.

Hence, it is necessary to fully

understand the stability and clearance of the system. Each component can be tracked
independently by isotope or dye labeling, which may allow us to identify weaker
interactions that are responsible for instability.
We expect the His-tagged membrane would dissociate into fragments and individual
peptides, which may be cleared by lymphatic drainage and renal clearance. Nonetheless,
there is no mechanism to control the degradation process especially considering the
peptides are relatively resistant to proteolysis (58).

Self-assembling peptides that are

sensitive to intrinsic enzymes, such as matrix metalloproteinase, have been investigated
(200).

Alternatively, hydrolytically susceptible peptides, depsipeptide, have been

synthesized (201). These strategies may be explored to improve the biodegradability of
our antibody display system.

159

This antibody display system may serve as a platform for two purposes in clinical
applications. First, it may be used as a local antibody delivery system to minimize
systemic exposure. Our data show that it could effectively retain antibodies in tumors,
subcutaneous spaces and the graft-host interface. The ability to reduce IgG clearance
opens opportunities for using therapeutic antibodies to modulate disease-associated T
cells. These include anti-CTLA-4 IgG that amplifies T cell responses toward cancers.
Intravenous infusion of these agents has been associated with immune related toxicities
due to non-specific effects on bystander leukocytes (138). An effective local depot could
mitigate these complications. Second, it may be used as a material strategy to interact
with target cells. It had been demonstrated that the trafficking of dAPCs was impeded in
a mouse skin transplantation model. Antibodies targeting cell surface molecules could be
displayed onto the in situ forming membranes to immobilize target cells, such as DCs and
T cells. Therefore, immunity that depends on these cells can be modulated. More
importantly, this strategy can be used in combination with existing immune modulating
reagents, for instance, cyclosporine A and tacrolimus. Each DC may activate 100-3,000
T cells (170). By capturing DCs using the antibody display system, doses of immune
suppressant may decrease to a level that unwanted side effects would be mitigated. In
summary, an injectable, biocompatible, and versatile material platform for antibody
display has been developed and characterized.

It may be utilized to deliver antibodies

locally to neutralize soluble antigens and display antibodies in situ to interact with target
cells.

It has the potential to improve therapeutic outcomes of mAbs.

Further

characterization and optimization would help translate it into clinical applications, such
as cancer and transplantation.
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